Hubbry Logo
Immune systemImmune systemMain
Open search
Immune system
Community hub
Immune system
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Immune system
Immune system
from Wikipedia

Immune system
A scanning electron microscope image of a single neutrophil (yellow/right), engulfing anthrax bacteria (orange/left) – scale bar is 5 μm (false color)
Identifiers
MeSHD007107
FMA9825
Anatomical terminology

The immune system is a network of biological systems that protects an organism from diseases. It detects and responds to a wide variety of pathogens, such as viruses, bacteria, and parasites, as well as cancer cells and objects, such as wood splinters—distinguishing them from the organism's own healthy tissue. Many species have two major subsystems of the immune system. The innate immune system provides a preconfigured response to broad groups of situations and stimuli. The adaptive immune system provides a tailored response to each stimulus by learning to recognize molecules it has previously encountered. Both use molecules and cells to perform their functions.

Nearly all organisms have some kind of immune system. Bacteria have a rudimentary immune system in the form of enzymes that protect against viral infections. Other basic immune mechanisms evolved in ancient plants and animals and remain in their modern descendants. These mechanisms include phagocytosis, antimicrobial peptides called defensins, and the complement system. Jawed vertebrates, including humans, have even more sophisticated defense mechanisms, including the ability to adapt to recognize pathogens more efficiently. Adaptive (or acquired) immunity creates an immunological memory leading to an enhanced response to subsequent encounters with that same pathogen. This process of acquired immunity is the basis of vaccination.

Dysfunction of the immune system can cause autoimmune diseases, inflammatory diseases and cancer. Immunodeficiency occurs when the immune system is less active than normal, resulting in recurring and life-threatening infections. In humans, immunodeficiency can be the result of a genetic disease such as severe combined immunodeficiency, acquired conditions such as HIV/AIDS, or the use of immunosuppressive medication. Autoimmunity results from a hyperactive immune system attacking normal tissues as if they were foreign organisms. Common autoimmune diseases include Hashimoto's thyroiditis, rheumatoid arthritis, diabetes mellitus type 1, and systemic lupus erythematosus. Immunology covers the study of all aspects of the immune system.

Layered defense

[edit]

The immune system protects its host from infection with layered defenses of increasing specificity. Physical barriers prevent pathogens such as bacteria and viruses from entering the organism.[1] If a pathogen breaches these barriers, the innate immune system provides an immediate, but non-specific response. Innate immune systems are found in all animals.[2] If pathogens successfully evade the innate response, vertebrates possess a second layer of protection, the adaptive immune system, which is activated by the innate response.[3] Here, the immune system adapts its response during an infection to improve its recognition of the pathogen. This improved response is then retained after the pathogen has been eliminated, in the form of an immunological memory, and allows the adaptive immune system to mount faster and stronger attacks each time this pathogen is encountered.[4][5]

Components of the immune system
Innate immune system Adaptive immune system
Response is non-specific Pathogen and antigen specific response
Exposure leads to immediate maximal response Lag time between exposure and maximal response
Cell-mediated and humoral components Cell-mediated and humoral components
No immunological memory Exposure leads to immunological memory
Found in nearly all forms of life Found only in jawed vertebrates

Both innate and adaptive immunity depend on the ability of the immune system to distinguish between self and non-self molecules. In immunology, self molecules are components of an organism's body that can be distinguished from foreign substances by the immune system.[6] Conversely, non-self molecules are those recognized as foreign molecules. One class of non-self molecules are called antigens (originally named for being antibody generators) and are defined as substances that bind to specific immune receptors and elicit an immune response.[7]

Surface barriers

[edit]

Several barriers protect organisms from infection, including mechanical, chemical, and biological barriers. The waxy cuticle of most leaves, the exoskeleton of insects, the shells and membranes of externally deposited eggs, and skin are examples of mechanical barriers that are the first line of defense against infection.[8] Organisms cannot be completely sealed from their environments, so systems act to protect body openings such as the lungs, intestines, and the genitourinary tract. In the lungs, coughing and sneezing mechanically eject pathogens and other irritants from the respiratory tract. The flushing action of tears and urine also mechanically expels pathogens, while mucus secreted by the respiratory and gastrointestinal tract serves to trap and entangle microorganisms.[9]

Chemical barriers also protect against infection. The skin and respiratory tract secrete antimicrobial peptides such as the β-defensins.[10] Enzymes such as lysozyme and phospholipase A2 in saliva, tears, and breast milk are also antibacterials.[11][12] Vaginal secretions serve as a chemical barrier following menarche, when they become slightly acidic, while semen contains defensins and zinc to kill pathogens.[13][14] In the stomach, gastric acid serves as a chemical defense against ingested pathogens.[15]

Within the genitourinary and gastrointestinal tracts, commensal flora serve as biological barriers by competing with pathogenic bacteria for food and space and, in some cases, changing the conditions in their environment, such as pH or available iron. As a result, the probability that pathogens will reach sufficient numbers to cause illness is reduced.[16]

Innate immune system

[edit]

Microorganisms or toxins that successfully enter an organism encounter the cells and mechanisms of the innate immune system. The innate response is usually triggered when microbes are identified by pattern recognition receptors, which recognize components that are conserved among broad groups of microorganisms,[17] or when damaged, injured or stressed cells send out alarm signals, many of which are recognized by the same receptors as those that recognize pathogens.[18] Innate immune defenses are non-specific, meaning these systems respond to pathogens in a generic way.[19] This system does not confer long-lasting immunity against a pathogen. The innate immune system is the dominant system of host defense in most organisms,[2] and the only one in plants.[20]

Immune sensing

[edit]

Cells in the innate immune system use pattern recognition receptors to recognize molecular structures that are produced by pathogens.[21] They are proteins expressed, mainly, by cells of the innate immune system, such as dendritic cells, macrophages, monocytes, neutrophils, and epithelial cells,[19][22] to identify two classes of molecules: pathogen-associated molecular patterns (PAMPs), which are associated with microbial pathogens, and damage-associated molecular patterns (DAMPs), which are associated with components of hosts' cells that are released during cell damage or cell death.[23] Cells in the innate immune system have pattern recognition receptors that detect internal infection or cell damage. Three major classes of these "cytosolic" receptors are NOD–like receptors, RIG (retinoic acid-inducible gene)-like receptors, and cytosolic DNA sensors.[24]

Recognition of extracellular or endosomal PAMPs is mediated by transmembrane proteins known as toll-like receptors (TLRs).[25] TLRs share a typical structural motif, the leucine rich repeats (LRRs), which give them a curved shape.[26] Toll-like receptors were first discovered in Drosophila and trigger the synthesis and secretion of cytokines and activation of other host defense programs that are necessary for both innate or adaptive immune responses. Ten toll-like receptors have been described in humans.[27]

Innate immune cells

[edit]
See caption
A scanning electron microscope image of normal circulating human blood. One can see red blood cells, several knobby white blood cells, including lymphocytes, a monocyte, and a neutrophil, and many small disc-shaped platelets.

Some leukocytes (white blood cells) act like independent, single-celled organisms and are the second arm of the innate immune system. The innate leukocytes include the "professional" phagocytes (macrophages, neutrophils, and dendritic cells). These cells identify and eliminate pathogens, either by attacking larger pathogens through contact or by engulfing and then killing microorganisms. The other cells involved in the innate response include innate lymphoid cells, mast cells, eosinophils, basophils, and natural killer cells.[28]

Phagocytosis is an important feature of cellular innate immunity performed by cells called phagocytes that engulf pathogens or particles. Phagocytes generally patrol the body searching for pathogens, but can be called to specific locations by cytokines.[29] Once a pathogen has been engulfed by a phagocyte, it becomes trapped in an intracellular vesicle called a phagosome, which subsequently fuses with another vesicle called a lysosome to form a phagolysosome. The pathogen is killed by the activity of digestive enzymes or following a respiratory burst that releases free radicals into the phagolysosome.[30][31] Phagocytosis evolved as a means of acquiring nutrients, but this role was extended in phagocytes to include engulfment of pathogens as a defense mechanism.[32] Phagocytosis probably represents the oldest form of host defense, as phagocytes have been identified in both vertebrate and invertebrate animals.[33]

Neutrophils and macrophages are phagocytes that travel throughout the body in pursuit of invading pathogens.[34] Neutrophils are normally found in the bloodstream and are the most abundant type of phagocyte, representing 50% to 60% of total circulating leukocytes.[35] During the acute phase of inflammation, neutrophils migrate toward the site of inflammation in a process called chemotaxis and are usually the first cells to arrive at the scene of infection. Macrophages are versatile cells that reside within tissues and produce an array of chemicals including enzymes, complement proteins, and cytokines. They can also act as scavengers that rid the body of worn-out cells and other debris and as antigen-presenting cells (APCs) that activate the adaptive immune system.[36]

Dendritic cells are phagocytes in tissues that are in contact with the external environment; therefore, they are located mainly in the skin, nose, lungs, stomach, and intestines.[37] They are named for their resemblance to neuronal dendrites, as both have many spine-like projections. Dendritic cells serve as a link between the bodily tissues and the innate and adaptive immune systems, as they present antigens to T cells, one of the key cell types of the adaptive immune system.[37]

Granulocytes are leukocytes that have granules in their cytoplasm. In this category are neutrophils, mast cells, basophils, and eosinophils. Mast cells reside in connective tissues and mucous membranes and regulate the inflammatory response.[38] They are most often associated with allergy and anaphylaxis.[35] Basophils and eosinophils are related to neutrophils. They secrete chemical mediators that are involved in defending against parasites and play a role in allergic reactions, such as asthma.[39]

Innate lymphoid cells (ILCs) are a group of innate immune cells that are derived from common lymphoid progenitor and belong to the lymphoid lineage. These cells are defined by the absence of antigen-specific B- or T-cell receptor (TCR) because of the lack of recombination activating gene. ILCs do not express myeloid or dendritic cell markers.[40]

Natural killer cells (NK cells) are lymphocytes and a component of the innate immune system that does not directly attack invading microbes.[41] Rather, NK cells destroy compromised host cells, such as tumor cells or virus-infected cells, recognizing such cells by a condition known as "missing self". This term describes cells with low levels of a cell-surface marker called MHC I (major histocompatibility complex)—a situation that can arise in viral infections of host cells.[42] Normal body cells are not recognized and attacked by NK cells because they express intact self MHC antigens. Those MHC antigens are recognized by killer cell immunoglobulin receptors, which essentially put the brakes on NK cells.[43]

Inflammation

[edit]

Inflammation is one of the first responses of the immune system to infection.[44] The symptoms of inflammation are redness, swelling, heat, and pain, which are caused by increased blood flow into tissue. Inflammation is produced by eicosanoids and cytokines, which are released by injured or infected cells. Eicosanoids include prostaglandins that produce fever and the dilation of blood vessels associated with inflammation and leukotrienes that attract certain white blood cells (leukocytes).[45][46] Common cytokines include interleukins that are responsible for communication between white blood cells; chemokines that promote chemotaxis; and interferons that have antiviral effects, such as shutting down protein synthesis in the host cell.[47] Growth factors and cytotoxic factors may also be released. These cytokines and other chemicals recruit immune cells to the site of infection and promote the healing of any damaged tissue following the removal of pathogens.[48] The pattern-recognition receptors called inflammasomes are multiprotein complexes (consisting of an NLR, the adaptor protein ASC, and the effector molecule pro-caspase-1) that form in response to cytosolic PAMPs and DAMPs, whose function is to generate active forms of the inflammatory cytokines IL-1β and IL-18.[49]

Humoral defenses

[edit]

The complement system is a biochemical cascade that attacks the surfaces of foreign cells. It contains over 20 different proteins and is named for its ability to "complement" the killing of pathogens by antibodies. Complement is the major humoral component of the innate immune response.[50][51] Many species have complement systems, including non-mammals like plants, fish, and some invertebrates.[52] In humans, this response is activated by complement binding to antibodies that have attached to these microbes or the binding of complement proteins to carbohydrates on the surfaces of microbes. This recognition signal triggers a rapid killing response.[53] The speed of the response is a result of signal amplification that occurs after sequential proteolytic activation of complement molecules, which are also proteases. After complement proteins initially bind to the microbe, they activate their protease activity, which in turn activates other complement proteases, and so on. This produces a catalytic cascade that amplifies the initial signal by controlled positive feedback.[54] The cascade results in the production of peptides that attract immune cells, increase vascular permeability, and opsonize (coat) the surface of a pathogen, marking it for destruction. This deposition of complement can also kill cells directly by disrupting their plasma membrane via the formation of a membrane attack complex.[50]

Adaptive immune system

[edit]
diagram showing the processes of activation, cell destruction and digestion, antibody production and proliferation, and response memory
Overview of the processes involved in the primary immune response

The adaptive immune system evolved in early vertebrates and allows for a stronger immune response as well as immunological memory, where each pathogen is "remembered" by a signature antigen.[55] The adaptive immune response is antigen-specific and requires the recognition of specific "non-self" antigens during a process called antigen presentation. Antigen specificity allows for the generation of responses that are tailored to specific pathogens or pathogen-infected cells. The ability to mount these tailored responses is maintained in the body by "memory cells". Should a pathogen infect the body more than once, these specific memory cells are used to quickly eliminate it.[56]

Recognition of antigen

[edit]

The cells of the adaptive immune system are special types of leukocytes, called lymphocytes. B cells and T cells are the major types of lymphocytes and are derived from hematopoietic stem cells in the bone marrow.[57] B cells are involved in the humoral immune response, whereas T cells are involved in cell-mediated immune response. Killer T cells only recognize antigens coupled to Class I MHC molecules, while helper T cells and regulatory T cells only recognize antigens coupled to Class II MHC molecules. These two mechanisms of antigen presentation reflect the different roles of the two types of T cell. A third, minor subtype are the γδ T cells that recognize intact antigens that are not bound to MHC receptors.[58] The double-positive T cells are exposed to a wide variety of self-antigens in the thymus, in which iodine is necessary for its thymus development and activity.[59] In contrast, the B cell antigen-specific receptor is an antibody molecule on the B cell surface and recognizes native (unprocessed) antigen without any need for antigen processing. Such antigens may be large molecules found on the surfaces of pathogens, but can also be small haptens (such as penicillin) attached to carrier molecule.[60] Each lineage of B cell expresses a different antibody, so the complete set of B cell antigen receptors represent all the antibodies that the body can manufacture.[57] When B or T cells encounter their related antigens they multiply and many "clones" of the cells are produced that target the same antigen. This is called clonal selection.[61]

Antigen presentation to T lymphocytes

[edit]

Both B cells and T cells carry receptor molecules that recognize specific targets. T cells recognize a "non-self" target, such as a pathogen, only after antigens (small fragments of the pathogen) have been processed and presented in combination with a "self" receptor called a major histocompatibility complex (MHC) molecule.[62]

Cell mediated immunity

[edit]

There are two major subtypes of T cells: the killer T cell and the helper T cell. In addition there are regulatory T cells which have a role in modulating immune response.[63]

Killer T cells

[edit]

Killer T cells are a sub-group of T cells that kill cells that are infected with viruses (and other pathogens), or are otherwise damaged or dysfunctional.[64] As with B cells, each type of T cell recognizes a different antigen. Killer T cells are activated when their T-cell receptor binds to this specific antigen in a complex with the MHC Class I receptor of another cell. Recognition of this MHC:antigen complex is aided by a co-receptor on the T cell, called CD8. The T cell then travels throughout the body in search of cells where the MHC I receptors bear this antigen. When an activated T cell contacts such cells, it releases cytotoxins, such as perforin, which form pores in the target cell's plasma membrane, allowing ions, water and toxins to enter. The entry of another toxin called granulysin (a protease) induces the target cell to undergo apoptosis.[65] T cell killing of host cells is particularly important in preventing the replication of viruses. T cell activation is tightly controlled and generally requires a very strong MHC/antigen activation signal, or additional activation signals provided by "helper" T cells (see below).[65]

Helper T cells

[edit]
Activation of macrophage or B cell by T helper cell

Helper T cells regulate both the innate and adaptive immune responses and help determine which immune responses the body makes to a particular pathogen.[66][67] These cells have no cytotoxic activity and do not kill infected cells or clear pathogens directly. They instead control the immune response by directing other cells to perform these tasks.[68]

Helper T cells express T cell receptors that recognize antigen bound to Class II MHC molecules. The MHC:antigen complex is also recognized by the helper cell's CD4 co-receptor, which recruits molecules inside the T cell (such as Lck) that are responsible for the T cell's activation. Helper T cells have a weaker association with the MHC:antigen complex than observed for killer T cells, meaning many receptors (around 200–300) on the helper T cell must be bound by an MHC:antigen to activate the helper cell, while killer T cells can be activated by engagement of a single MHC:antigen molecule. Helper T cell activation also requires longer duration of engagement with an antigen-presenting cell.[69] The activation of a resting helper T cell causes it to release cytokines that influence the activity of many cell types. Cytokine signals produced by helper T cells enhance the microbicidal function of macrophages and the activity of killer T cells.[70] In addition, helper T cell activation causes an upregulation of molecules expressed on the T cell's surface, such as CD40 ligand (also called CD154), which provide extra stimulatory signals typically required to activate antibody-producing B cells.[71]

Gamma delta T cells

[edit]

Gamma delta T cells (γδ T cells) possess an alternative T-cell receptor (TCR) as opposed to CD4+ and CD8+ (αβ) T cells and share the characteristics of helper T cells, cytotoxic T cells and NK cells. The conditions that produce responses from γδ T cells are not fully understood. Like other 'unconventional' T cell subsets bearing invariant TCRs, such as CD1d-restricted natural killer T cells, γδ T cells straddle the border between innate and adaptive immunity.[72] On one hand, γδ T cells are a component of adaptive immunity as they rearrange TCR genes to produce receptor diversity and can also develop a memory phenotype. On the other hand, the various subsets are also part of the innate immune system, as restricted TCR or NK receptors may be used as pattern recognition receptors. For example, large numbers of human Vγ9/Vδ2 T cells respond within hours to common molecules produced by microbes, and highly restricted Vδ1+ T cells in epithelia respond to stressed epithelial cells.[58]

Humoral immune response

[edit]
diagram showing the Y-shaped antibody. The variable region, including the antigen-binding site, is the top part of the two upper light chains. The remainder is the constant region.
An antibody is made up of two heavy chains and two light chains. The unique variable region allows an antibody to recognize its matching antigen.[73]

A B cell identifies pathogens when antibodies on its surface bind to a specific foreign antigen.[74] This antigen/antibody complex is taken up by the B cell and processed by proteolysis into peptides. The B cell then displays these antigenic peptides on its surface MHC class II molecules. This combination of MHC and antigen attracts a matching helper T cell, which releases lymphokines and activates the B cell.[75] As the activated B cell then begins to divide, its offspring (plasma cells) secrete millions of copies of the antibody that recognizes this antigen. These antibodies circulate in blood plasma and lymph, bind to pathogens expressing the antigen and mark them for destruction by complement activation or for uptake and destruction by phagocytes. Antibodies can also neutralize challenges directly, by binding to bacterial toxins or by interfering with the receptors that viruses and bacteria use to infect cells.[76]

Newborn infants have no prior exposure to microbes and are particularly vulnerable to infection. Several layers of passive protection are provided by the mother. During pregnancy, a particular type of antibody, called IgG, is transported from mother to baby directly through the placenta, so human babies have high levels of antibodies even at birth, with the same range of antigen specificities as their mother.[77] Breast milk or colostrum also contains antibodies that are transferred to the gut of the infant and protect against bacterial infections until the newborn can synthesize its own antibodies.[78] This is passive immunity because the fetus does not actually make any memory cells or antibodies—it only borrows them. This passive immunity is usually short-term, lasting from a few days up to several months. In medicine, protective passive immunity can also be transferred artificially from one individual to another.[79]

Immunological memory

[edit]

When B cells and T cells are activated and begin to replicate, some of their offspring become long-lived memory cells. Throughout the lifetime of an animal, these memory cells remember each specific pathogen encountered and can mount a strong response if the pathogen is detected again. T-cells recognize pathogens by small protein-based infection signals, called antigens, that bind directly to T-cell surface receptors.[80] B-cells use the protein, immunoglobulin, to recognize pathogens by their antigens.[81] This is "adaptive" because it occurs during the lifetime of an individual as an adaptation to infection with that pathogen and prepares the immune system for future challenges. Immunological memory can be in the form of either passive short-term memory or active long-term memory.[82]

Physiological regulation

[edit]
The initial response involves antibody and effector T-cells. The resulting protective immunity lasts for weeks. Immunological memory often lasts for years.
The time-course of an immune response begins with the initial pathogen encounter, (or initial vaccination) and leads to the formation and maintenance of active immunological memory.

The immune system is involved in many aspects of physiological regulation in the body. The immune system interacts intimately with other systems, such as the endocrine[83][84] and the nervous[85][86][87] systems. The immune system also plays a crucial role in embryogenesis (development of the embryo), as well as in tissue repair and regeneration.[88]

Hormones

[edit]

Hormones can act as immunomodulators, altering the sensitivity of the immune system. For example, female sex hormones are known immunostimulators of both adaptive[89] and innate immune responses.[90] Some autoimmune diseases such as lupus erythematosus strike women preferentially, and their onset often coincides with puberty. By contrast, male sex hormones such as testosterone seem to be immunosuppressive.[91] Other hormones appear to regulate the immune system as well, most notably prolactin, growth hormone and vitamin D.[92][93]

Vitamin D

[edit]

Although early cellular studies suggested vitamin D might influence immune responses, more recent large-scale clinical trials and meta-analyses (2022–2024) have found that vitamin D supplementation can reduce the risk and severity of autoimmune diseases such as rheumatoid arthritis and multiple sclerosis, and may modestly reduce the incidence of acute respiratory tract infections and improve tuberculosis outcomes.[94][95][96] A 2011 United States Institute of Medicine report stated that "outcomes related to ... immune functioning and autoimmune disorders, and infections ... could not be linked reliably with calcium or vitamin D intake and were often conflicting."[97]: 5 

Sleep and rest

[edit]

The immune system is affected by sleep and rest, and sleep deprivation is detrimental to immune function.[98] Complex feedback loops involving cytokines, such as interleukin-1 and tumor necrosis factor-α produced in response to infection, appear to also play a role in the regulation of non-rapid eye movement (NREM) sleep.[99] Thus the immune response to infection may result in changes to the sleep cycle, including an increase in slow-wave sleep relative to rapid eye movement (REM) sleep.[100]

In people with sleep deprivation, active immunizations may have a diminished effect and may result in lower antibody production, and a lower immune response, than would be noted in a well-rested individual.[101][102] Additionally, proteins such as NFIL3, which have been shown to be closely intertwined with both T-cell differentiation and circadian rhythms, can be affected through the disturbance of natural light and dark cycles through instances of sleep deprivation. These disruptions can lead to an increase in chronic conditions such as heart disease, chronic pain, and asthma.[103]

In addition to the negative consequences of sleep deprivation, sleep and the intertwined circadian system have been shown to have strong regulatory effects on immunological functions affecting both innate and adaptive immunity. First, during the early slow-wave-sleep stage, a sudden drop in blood levels of cortisol, epinephrine, and norepinephrine causes increased blood levels of the hormones leptin, pituitary growth hormone, and prolactin. These signals induce a pro-inflammatory state through the production of the pro-inflammatory cytokines interleukin-1, interleukin-12, TNF-alpha and IFN-gamma. These cytokines then stimulate immune functions such as immune cell activation, proliferation, and differentiation. During this time of a slowly evolving adaptive immune response, there is a peak in undifferentiated or less differentiated cells, like naïve and central memory T cells. In addition to these effects, the milieu of hormones produced at this time (leptin, pituitary growth hormone, and prolactin) supports the interactions between APCs and T-cells, a shift of the Th1/Th2 cytokine balance towards one that supports Th1, an increase in overall Th cell proliferation, and naïve T cell migration to lymph nodes. This is also thought to support the formation of long-lasting immune memory through the initiation of Th1 immune responses.[104]

During wake periods, differentiated effector cells, such as cytotoxic natural killer cells and CD45RA+ cytotoxic T lymphocytes, peak in numbers. Anti-inflammatory molecules, such as cortisol and catecholamines, also peak during awake active times. Inflammation can cause oxidative stress and the presence of melatonin during sleep times could counteract free radical production during this time.[104][105]

Physical exercise

[edit]

Physical exercise has a positive effect on the immune system and depending on the frequency and intensity, the pathogenic effects of diseases caused by bacteria and viruses are moderated.[106] Immediately after intense exercise there is a transient immunodepression, where the number of circulating lymphocytes decreases and antibody production declines. This may give rise to a window of opportunity for infection and reactivation of latent virus infections,[107] but the evidence is inconclusive.[108][109]

Changes at the cellular level

[edit]
Four neutrophils in a Giemsa-stained blood film

During exercise there is an increase in circulating white blood cells of all types. This is caused by the frictional force of blood flowing on the endothelial cell surface and catecholamines affecting β-adrenergic receptors (βARs).[107] The number of neutrophils in the blood increases and remains raised for up to six hours and immature forms are present. Although the increase in neutrophils ("neutrophilia") is similar to that seen during bacterial infections, after exercise the cell population returns to normal by around 24 hours.[107]

The number of circulating lymphocytes (mainly natural killer cells) decreases during intense exercise but returns to normal after 4 to 6 hours. Although up to 2% of the cells die most migrate from the blood to the tissues, mainly the intestines and lungs, where pathogens are most likely to be encountered.[107]

Some monocytes leave the blood circulation and migrate to the muscles where they differentiate and become macrophages.[107] These cells differentiate into two types: proliferative macrophages, which are responsible for increasing the number of stem cells and restorative macrophages, which are involved their maturing to muscle cells.[110]

Repair and regeneration

[edit]

The immune system, particularly the innate component, plays a decisive role in tissue repair after an insult. Key actors include macrophages and neutrophils, but other cellular actors, including γδ T cells, innate lymphoid cells (ILCs), and regulatory T cells (Tregs), are also important. The plasticity of immune cells and the balance between pro-inflammatory and anti-inflammatory signals are crucial aspects of efficient tissue repair. Immune components and pathways are involved in regeneration as well, for example in amphibians such as in axolotl limb regeneration. According to one hypothesis, organisms that can regenerate (e.g., axolotls) could be less immunocompetent than organisms that cannot regenerate.[111]

Disorders of human immunity

[edit]

Failures of host defense occur and fall into three broad categories: immunodeficiencies,[112] autoimmunity,[113] and hypersensitivities.[114]

Immunodeficiencies

[edit]

Immunodeficiencies occur when one or more of the components of the immune system are inactive. The ability of the immune system to respond to pathogens is diminished in both the young and the elderly, with immune responses beginning to decline at around 50 years of age due to immunosenescence.[115][116] In developed countries, obesity, alcoholism, and drug use are common causes of poor immune function, while malnutrition is the most common cause of immunodeficiency in developing countries.[116] Diets lacking sufficient protein are associated with impaired cell-mediated immunity, complement activity, phagocyte function, IgA antibody concentrations, and cytokine production. Additionally, the loss of the thymus at an early age through genetic mutation or surgical removal results in severe immunodeficiency and a high susceptibility to infection.[117] Immunodeficiencies can also be inherited or 'acquired'.[118] Severe combined immunodeficiency is a rare genetic disorder characterized by the disturbed development of functional T cells and B cells caused by numerous genetic mutations.[119] Chronic granulomatous disease, where phagocytes have a reduced ability to destroy pathogens, is an example of an inherited, or congenital, immunodeficiency. AIDS and some types of cancer cause acquired immunodeficiency.[120][121]

Autoimmunity

[edit]
See caption
Joints of a hand swollen and deformed by rheumatoid arthritis, an autoimmune disorder

Overactive immune responses form the other end of immune dysfunction, particularly the autoimmune diseases. Here, the immune system fails to properly distinguish between self and non-self, and attacks part of the body. Under normal circumstances, many T cells and antibodies react with "self" peptides.[122] One of the functions of specialized cells (located in the thymus and bone marrow) is to present young lymphocytes with self antigens produced throughout the body and to eliminate those cells that recognize self-antigens, preventing autoimmunity.[74] Common autoimmune diseases include Hashimoto's thyroiditis,[123] rheumatoid arthritis,[124] diabetes mellitus type 1,[125] and systemic lupus erythematosus.[126]

Hypersensitivity

[edit]

Hypersensitivity is an immune response that damages the body's own tissues. It is divided into four classes (Type I – IV) based on the mechanisms involved and the time course of the hypersensitive reaction. Type I hypersensitivity is an immediate or anaphylactic reaction, often associated with allergy. Symptoms can range from mild discomfort to death. Type I hypersensitivity is mediated by IgE, which triggers degranulation of mast cells and basophils when cross-linked by antigen.[127] Type II hypersensitivity occurs when antibodies bind to antigens on the individual's own cells, marking them for destruction. This is also called antibody-dependent (or cytotoxic) hypersensitivity, and is mediated by IgG and IgM antibodies.[127] Immune complexes (aggregations of antigens, complement proteins, and IgG and IgM antibodies) deposited in various tissues trigger Type III hypersensitivity reactions.[127] Type IV hypersensitivity (also known as cell-mediated or delayed type hypersensitivity) usually takes between two and three days to develop. Type IV reactions are involved in many autoimmune and infectious diseases, but may also involve contact dermatitis. These reactions are mediated by T cells, monocytes, and macrophages.[127]

Idiopathic inflammation

[edit]

Inflammation is one of the first responses of the immune system to infection,[44] but it can appear without known cause.

Inflammation is produced by eicosanoids and cytokines, which are released by injured or infected cells. Eicosanoids include prostaglandins that produce fever and the dilation of blood vessels associated with inflammation, and leukotrienes that attract certain white blood cells (leukocytes).[45][46] Common cytokines include interleukins that are responsible for communication between white blood cells; chemokines that promote chemotaxis; and interferons that have anti-viral effects, such as shutting down protein synthesis in the host cell.[47] Growth factors and cytotoxic factors may also be released. These cytokines and other chemicals recruit immune cells to the site of infection and promote healing of any damaged tissue following the removal of pathogens.[48]

Manipulation in medicine

[edit]
Skeletal structural formula of dexamethasone, C22 H29 F O5
Skeletal structural formula of the immunosuppressive drug dexamethasone

The immune response can be manipulated to suppress unwanted responses resulting from autoimmunity, allergy, and transplant rejection, and to stimulate protective responses against pathogens that largely elude the immune system (see immunization) or cancer.[128]

Immunosuppression

[edit]

Immunosuppressive drugs are used to control autoimmune disorders or inflammation when excessive tissue damage occurs, and to prevent rejection after an organ transplant.[129][130]

Anti-inflammatory drugs are often used to control the effects of inflammation. Glucocorticoids are the most powerful of these drugs and can have many undesirable side effects, such as central obesity, hyperglycemia, and osteoporosis.[131] Their use is tightly controlled. Lower doses of anti-inflammatory drugs are often used in conjunction with cytotoxic or immunosuppressive drugs such as methotrexate or azathioprine.

Cytotoxic drugs inhibit the immune response by killing dividing cells such as activated T cells. This killing is indiscriminate and other constantly dividing cells and their organs are affected, which causes toxic side effects.[130] Immunosuppressive drugs such as cyclosporin prevent T cells from responding to signals correctly by inhibiting signal transduction pathways.[132]

Immunostimulation

[edit]

Claims made by marketers of various products and alternative health providers, such as chiropractors, homeopaths, and acupuncturists to be able to stimulate or "boost" the immune system generally lack meaningful explanation and evidence of effectiveness.[133]

Vaccination

[edit]
A child receiving drops of polio vaccine in her mouth
Polio vaccination in Egypt

Long-term active memory is acquired following infection by activation of B and T cells. Active immunity can also be generated artificially, through vaccination. The principle behind vaccination (also called immunization) is to introduce an antigen from a pathogen to stimulate the immune system and develop specific immunity against that particular pathogen without causing disease associated with that organism.[134] This deliberate induction of an immune response is successful because it exploits the natural specificity of the immune system, as well as its inducibility. With infectious disease remaining one of the leading causes of death in the human population, vaccination represents the most effective manipulation of the immune system mankind has developed.[57][135]

Many vaccines are based on acellular components of micro-organisms, including harmless toxin components.[134] Since many antigens derived from acellular vaccines do not strongly induce the adaptive response, most bacterial vaccines are provided with additional adjuvants that activate the antigen-presenting cells of the innate immune system and maximize immunogenicity.[136]

Tumor immunology

[edit]

Another important role of the immune system is to identify and eliminate tumors. This is called immune surveillance. The transformed cells of tumors express antigens that are not found on normal cells. To the immune system, these antigens appear foreign, and their presence causes immune cells to attack the transformed tumor cells. The antigens expressed by tumors have several sources;[137] some are derived from oncogenic viruses like human papillomavirus, which causes cancer of the cervix,[138] vulva, vagina, penis, anus, mouth, and throat,[139] while others are the organism's own proteins that occur at low levels in normal cells but reach high levels in tumor cells. One example is an enzyme called tyrosinase that, when expressed at high levels, transforms certain skin cells (for example, melanocytes) into tumors called melanomas.[140][141] A third possible source of tumor antigens are proteins normally important for regulating cell growth and survival, that commonly mutate into cancer inducing molecules called oncogenes.[137][142][143]

See caption
Macrophages have identified a cancer cell (the large, spiky mass). Upon fusing with the cancer cell, the macrophages (smaller white cells) inject toxins that kill the tumor cell. Immunotherapy for the treatment of cancer is an active area of medical research.[144]

The main response of the immune system to tumors is to destroy the abnormal cells using killer T cells, sometimes with the assistance of helper T cells.[141][145] Tumor antigens are presented on MHC class I molecules in a similar way to viral antigens. This allows killer T cells to recognize the tumor cell as abnormal.[146] NK cells also kill tumorous cells in a similar way, especially if the tumor cells have fewer MHC class I molecules on their surface than normal; this is a common phenomenon with tumors.[147] Sometimes antibodies are generated against tumor cells allowing for their destruction by the complement system.[142]

Some tumors evade the immune system and go on to become cancers.[148][149] Tumor cells often have a reduced number of MHC class I molecules on their surface, thus avoiding detection by killer T cells.[146][148] Some tumor cells also release products that inhibit the immune response; for example by secreting the cytokine TGF-β, which suppresses the activity of macrophages and lymphocytes.[148][150] In addition, immunological tolerance may develop against tumor antigens, so the immune system no longer attacks the tumor cells.[148][149]

Paradoxically, macrophages can promote tumor growth[151] when tumor cells send out cytokines that attract macrophages, which then generate cytokines and growth factors such as tumor-necrosis factor alpha that nurture tumor development or promote stem-cell-like plasticity.[148] In addition, a combination of hypoxia in the tumor and a cytokine produced by macrophages induces tumor cells to decrease production of a protein that blocks metastasis and thereby assists spread of cancer cells.[148] Anti-tumor M1 macrophages are recruited in early phases to tumor development but are progressively differentiated to M2 with pro-tumor effect, an immunosuppressor switch. The hypoxia reduces the cytokine production for the anti-tumor response and progressively macrophages acquire pro-tumor M2 functions driven by the tumor microenvironment, including IL-4 and IL-10.[152] Cancer immunotherapy covers the medical ways to stimulate the immune system to attack cancer tumors.[153]

Predicting immunogenicity

[edit]

Some drugs can cause a neutralizing immune response, meaning that the immune system produces neutralizing antibodies that counteract the action of the drugs, particularly if the drugs are administered repeatedly, or in larger doses. This limits the effectiveness of drugs based on larger peptides and proteins (which are typically larger than 6000 Da).[154] In some cases, the drug itself is not immunogenic, but may be co-administered with an immunogenic compound, as is sometimes the case for Taxol. Computational methods have been developed to predict the immunogenicity of peptides and proteins, which are particularly useful in designing therapeutic antibodies, assessing likely virulence of mutations in viral coat particles, and validation of proposed peptide-based drug treatments. Early techniques relied mainly on the observation that hydrophilic amino acids are overrepresented in epitope regions than hydrophobic amino acids;[155] however, more recent developments rely on machine learning techniques using databases of existing known epitopes, usually on well-studied virus proteins, as a training set.[156] A publicly accessible database has been established for the cataloguing of epitopes from pathogens known to be recognizable by B cells.[157] The emerging field of bioinformatics-based studies of immunogenicity is referred to as immunoinformatics.[158] Immunoproteomics is the study of large sets of proteins (proteomics) involved in the immune response.[159]

Evolution and other mechanisms

[edit]

Evolution of the immune system

[edit]

It is likely that a multicomponent, adaptive immune system arose with the first vertebrates, as invertebrates do not generate lymphocytes or an antibody-based humoral response.[160] Immune systems evolved in deuterostomes as shown in the cladogram.[160]

Deuterostomes
innate immunity

Many species, however, use mechanisms that appear to be precursors of these aspects of vertebrate immunity. Immune systems appear even in the structurally simplest forms of life, with bacteria using a unique defense mechanism, called the restriction modification system to protect themselves from viral pathogens, called bacteriophages.[161] Prokaryotes (bacteria and archaea) also possess acquired immunity, through a system that uses CRISPR sequences to retain fragments of the genomes of phage that they have come into contact with in the past, which allows them to block virus replication through a form of RNA interference.[162][163] Prokaryotes also possess other defense mechanisms.[164][165] Offensive elements of the immune systems are also present in unicellular eukaryotes, but studies of their roles in defense are few.[166]

Pattern recognition receptors are proteins used by nearly all organisms to identify molecules associated with pathogens. Antimicrobial peptides called defensins are an evolutionarily conserved component of the innate immune response found in all animals and plants, and represent the main form of invertebrate systemic immunity.[160] The complement system and phagocytic cells are also used by most forms of invertebrate life. Ribonucleases and the RNA interference pathway are conserved across all eukaryotes, and are thought to play a role in the immune response to viruses.[167]

Unlike animals, plants lack phagocytic cells, but many plant immune responses involve systemic chemical signals that are sent through a plant.[168] Individual plant cells respond to molecules associated with pathogens known as pathogen-associated molecular patterns or PAMPs.[169] When a part of a plant becomes infected, the plant produces a localized hypersensitive response, whereby cells at the site of infection undergo rapid apoptosis to prevent the spread of the disease to other parts of the plant. Systemic acquired resistance is a type of defensive response used by plants that renders the entire plant resistant to a particular infectious agent.[168] RNA silencing mechanisms are particularly important in this systemic response as they can block virus replication.[170]

Alternative adaptive immune system

[edit]

Evolution of the adaptive immune system occurred in an ancestor of the jawed vertebrates. Many of the classical molecules of the adaptive immune system (for example, immunoglobulins and T-cell receptors) exist only in jawed vertebrates. A distinct lymphocyte-derived molecule has been discovered in primitive jawless vertebrates, such as the lamprey and hagfish. These animals possess a large array of molecules called Variable lymphocyte receptors (VLRs) that, like the antigen receptors of jawed vertebrates, are produced from only a small number (one or two) of genes. These molecules are believed to bind pathogenic antigens in a similar way to antibodies, and with the same degree of specificity.[171]

Manipulation by pathogens

[edit]

The success of any pathogen depends on its ability to elude host immune responses. Therefore, pathogens evolved several methods that allow them to successfully infect a host, while evading detection or destruction by the immune system.[172] Bacteria often overcome physical barriers by secreting enzymes that digest the barrier, for example, by using a type II secretion system.[173] Alternatively, using a type III secretion system, they may insert a hollow tube into the host cell, providing a direct route for proteins to move from the pathogen to the host. These proteins are often used to shut down host defenses.[174]

An evasion strategy used by several pathogens to avoid the innate immune system is to hide within the cells of their host (also called intracellular pathogenesis). Here, a pathogen spends most of its life-cycle inside host cells, where it is shielded from direct contact with immune cells, antibodies and complement. Some examples of intracellular pathogens include viruses, the food poisoning bacterium Salmonella and the eukaryotic parasites that cause malaria (Plasmodium spp.) and leishmaniasis (Leishmania spp.). Other bacteria, such as Mycobacterium tuberculosis, live inside a protective capsule that prevents lysis by complement.[175] Many pathogens secrete compounds that diminish or misdirect the host's immune response.[172] Some bacteria form biofilms to protect themselves from the cells and proteins of the immune system. Such biofilms are present in many successful infections, such as the chronic Pseudomonas aeruginosa and Burkholderia cenocepacia infections characteristic of cystic fibrosis.[176] Other bacteria generate surface proteins that bind to antibodies, rendering them ineffective; examples include Streptococcus (protein G), Staphylococcus aureus (protein A), and Peptostreptococcus magnus (protein L).[177]

The mechanisms used to evade the adaptive immune system are more complicated. The simplest approach is to rapidly change non-essential epitopes (amino acids and/or sugars) on the surface of the pathogen, while keeping essential epitopes concealed. This is called antigenic variation. An example is HIV, which mutates rapidly, so the proteins on its viral envelope that are essential for entry into its host target cell are constantly changing. These frequent changes in antigens may explain the failures of vaccines directed at this virus.[178] The parasite Trypanosoma brucei uses a similar strategy, constantly switching one type of surface protein for another, allowing it to stay one step ahead of the antibody response.[179] Masking antigens with host molecules is another common strategy for avoiding detection by the immune system. In HIV, the envelope that covers the virion is formed from the outermost membrane of the host cell; such "self-cloaked" viruses make it difficult for the immune system to identify them as "non-self" structures.[180]

History of immunology

[edit]
Portrait of an older, thin man with a beard wearing glasses and dressed in a suit and tie
Paul Ehrlich (1854–1915) was awarded a Nobel Prize in 1908 for his contributions to immunology.[181]

Immunology is a science that examines the structure and function of the immune system. It originates from medicine and early studies on the causes of immunity to disease. The earliest known reference to immunity was during the plague of Athens in 430 BC. Thucydides noted that people who had recovered from a previous bout of the disease could nurse the sick without contracting the illness a second time.[182] In the 18th century, Pierre-Louis Moreau de Maupertuis experimented with scorpion venom and observed that certain dogs and mice were immune to this venom.[183] In the 10th century, Persian physician al-Razi (also known as Rhazes) wrote the first recorded theory of acquired immunity,[184][185] noting that a smallpox bout protected its survivors from future infections. Although he explained the immunity in terms of "excess moisture" being expelled from the blood—therefore preventing a second occurrence of the disease—this theory explained many observations about smallpox known during this time.[186]

These and other observations of acquired immunity were later exploited by Louis Pasteur in his development of vaccination and his proposed germ theory of disease.[187] Pasteur's theory was in direct opposition to contemporary theories of disease, such as the miasma theory. It was not until Robert Koch's 1891 proofs, for which he was awarded a Nobel Prize in 1905, that microorganisms were confirmed as the cause of infectious disease.[188] Viruses were confirmed as human pathogens in 1901, with the discovery of the yellow fever virus by Walter Reed.[189]

Immunology made a great advance towards the end of the 19th century, through rapid developments in the study of humoral immunity and cellular immunity.[190] Particularly important was the work of Paul Ehrlich, who proposed the side-chain theory to explain the specificity of the antigen-antibody reaction; his contributions to the understanding of humoral immunity were recognized by the award of a joint Nobel Prize in 1908, along with the founder of cellular immunology, Elie Metchnikoff.[181] In 1974, Niels Kaj Jerne developed the immune network theory; he shared a Nobel Prize in 1984 with Georges J. F. Köhler and César Milstein for theories related to the immune system.[191][192]

See also

[edit]

References

[edit]

Further reading

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia
from Grokipedia
The immune system is a of cells, tissues, organs, and molecules that protects the body from harmful pathogens, such as , viruses, fungi, and parasites, as well as from abnormal or damaged cells, including cancer cells, by distinguishing between healthy self-cells and foreign or unhealthy entities. This defense mechanism operates through coordinated responses that prevent or limit infections, promote healing, and maintain overall , with all immune cells originating from precursor hematopoietic stem cells in the . The system is essential for survival, as its dysfunction can lead to infections, autoimmune diseases, allergies, or immunodeficiencies. The immune system comprises two main interconnected branches: the and the , which together provide layered protection against threats. The innate immune system serves as the first line of defense, offering rapid, non-specific responses to a broad range of pathogens within minutes to hours of exposure. It includes physical barriers like the skin and mucous membranes, chemical defenses such as antimicrobial proteins in saliva and tears, and cellular components that engulf or destroy invaders through processes like and . Key innate cells include neutrophils, macrophages, dendritic cells, and natural killer (NK) cells, which recognize general danger signals via pattern recognition receptors that detect pathogen-associated molecular patterns (PAMPs) or damage-associated molecular patterns (DAMPs). In contrast, the provides slower but highly specific and long-lasting protection, developing immunological memory to enable faster and stronger responses upon re-exposure to the same . It is mediated primarily by lymphocytes—B cells and T cells—which recognize unique antigens on pathogens through diverse receptors generated by . B cells produce antibodies that neutralize extracellular threats, while T cells include helper T cells that coordinate responses, cytotoxic T cells that kill infected or abnormal cells, and regulatory T cells that prevent overreactions. Adaptive immunity is triggered by signals from the innate system, such as cytokines released by innate cells, and can lead to lifelong immunity, as seen in . Central to the immune system's function are specialized organs and tissues that support cell development, maturation, and activation. Primary lymphoid organs include the , where most immune cells originate and B cells mature, and the , where T cells develop and learn to tolerate self-antigens. Secondary lymphoid organs, such as lymph nodes, the , and mucosal-associated lymphoid tissues () like Peyer's patches in the gut, serve as sites where immune cells encounter antigens drained from tissues via lymphatic vessels or , initiating targeted responses. Lymphocytes constantly recirculate through and to patrol the body, ensuring vigilant surveillance.

Fundamentals

Definition and components

The immune system is a complex network of cells, tissues, and organs that collectively defends the body against invading pathogens such as , viruses, and parasites while distinguishing between and non-self components to prevent . This defense mechanism is essential for maintaining and survival in multicellular organisms. The primary lymphoid organs, where immune cells originate and mature, include the and the . Bone marrow, located in the cavities of bones, serves as the site of hematopoiesis for all blood cells, including immune cells. The , situated in the upper chest, is crucial for the maturation of certain immune cells during early development. Secondary lymphoid organs, which facilitate immune responses by concentrating antigens and immune cells, encompass lymph nodes, the , and (MALT). Lymph nodes are distributed throughout the body along lymphatic vessels, the filters blood in the , and MALT lines mucosal surfaces such as those in the gut and . Key cellular components of the immune system are leukocytes, or , which circulate in the and . Leukocytes are broadly categorized into families: granulocytes, including neutrophils, , and , which contain cytoplasmic granules; and agranulocytes, comprising lymphocytes (such as T cells and B cells) and monocytes. These cell types, numbering approximately 4.5 to 11.0 × 10⁹ per liter in human , form the mobile workforce of the immune system. The immune system, particularly its adaptive branch, represents an evolutionary hallmark of jawed vertebrates, emerging over 500 million years ago to provide specific and memory-based against diverse threats.

Layered defense strategy

The immune system's layered defense functions as a hierarchical, multi-tiered mechanism designed to detect, neutralize, and eliminate with increasing specificity and efficiency. This approach consists of three primary lines of defense: the first line comprising physical and chemical barriers that prevent pathogen entry; the second line involving the innate , which provides rapid, nonspecific ; and the third line encompassing the adaptive , which offers targeted, memory-based immunity. This progression ensures that most threats are halted early, while those that penetrate deeper encounter escalating countermeasures, minimizing the risk of infection establishment. Redundancy is a core feature of this strategy, with overlapping mechanisms across layers to compensate for potential failures in any single component, thereby enhancing overall resilience. For instance, if the first-line barriers are compromised, such as through a abrasion, this immediately activates the second-line innate response, recruiting phagocytic cells and initiating to contain the breach. Cooperation between layers further amplifies effectiveness; the innate system not only bridges the gap between barriers and adaptive responses but also primes the latter by presenting antigens to T and B cells, fostering a coordinated escalation. The serves as the rapid, nonspecific second layer, responding within minutes to hours to conserved features via receptors. This biological efficiency mirrors historical military analogies, such as defenses where outer walls deter invaders before inner fortifications engage, but prioritizes adaptive redundancy over static fortification to handle diverse microbial threats dynamically.

Barriers and Initial Defenses

Physical barriers

The skin acts as the body's primary physical barrier against entry, comprising the , a multilayered structure that prevents microbial penetration. The outermost layer, the , consists of dead filled with , a tough protein that provides mechanical strength and impermeability to water and microbes. Beneath this, viable epidermal layers feature tight junctions between , which seal intercellular spaces and restrict the passage of and toxins into deeper tissues. Mucous membranes line the respiratory, gastrointestinal, and urogenital tracts, forming additional physical barriers by trapping and expelling potential invaders. In the , ciliated epithelial cells propel mucus upward via coordinated beating of cilia, carrying trapped particles and microbes away from the lungs toward the for expulsion. Similarly, in the , peristaltic movements propel contents along the intestines, mechanically flushing pathogens while the mucosal sheds cells to remove adherent microbes. The urogenital tract employs urine flow during to mechanically wash out from the urethra and , reducing risk. Other specialized barriers include the , which covers the eye's surface and uses a thin epithelial layer with goblet cells to secrete protective , preventing microbial adhesion. The blood-brain barrier, formed by tight junctions between endothelial cells in cerebral capillaries, selectively restricts entry into the , maintaining a sterile environment for neural tissues. These physical structures collectively provide the first line of defense, often complemented by chemical mechanisms for enhanced protection.

Chemical and antimicrobial barriers

The immune system's chemical and antimicrobial barriers consist of soluble molecules and environmental factors secreted at epithelial surfaces that inhibit or eliminate pathogens before they can invade deeper tissues. These defenses complement physical barriers such as and mucosa by providing biochemical deterrence directly at sites of potential microbial entry. , an enzyme abundant in , , and , serves as a key agent by hydrolyzing the β-1,4 glycosidic bonds in bacterial , leading to degradation and osmotic primarily of . This mechanism disrupts bacterial integrity at mucosal surfaces, preventing colonization in the eyes, , and . Antimicrobial peptides, including defensins and cathelicidins, form another critical layer of defense through direct pathogen disruption. Defensins, such as α-defensins produced by neutrophils and β-defensins by epithelial cells, are cationic peptides that insert into microbial membranes, forming pores via barrel-stave, carpet, or toroidal models, which compromise membrane integrity and cause leakage of cellular contents. Similarly, cathelicidins like the human LL-37 peptide, expressed in epithelial cells and neutrophils, adopt an amphipathic α-helical structure to permeabilize bacterial, fungal, and viral envelopes, enhancing barrier protection at skin and mucosal interfaces. Acidic environments provide a non-proteinaceous chemical barrier that denatures microbial proteins and enzymes. In the , hydrochloric acid maintains a of 1-3, which effectively kills ingested pathogens by disrupting their structural components and metabolic processes. The vaginal mucosa similarly sustains an acidic around 3.5-4.5 through produced by resident lactobacilli, inhibiting the growth of harmful and yeasts while supporting beneficial . The normal , consisting of commensal microorganisms residing on , in the gut, and at other mucosal sites, acts as a biological barrier by outcompeting pathogens for nutrients and attachment sites, producing metabolites such as and , and stimulating host immune maturation to prevent colonization by harmful invaders. Additional factors like and pulmonary contribute targeted effects. , an iron-binding present in , , nasal secretions, and , sequesters free iron essential for bacterial proliferation, thereby starving pathogens and limiting infections at mucosal sites. In the lungs, pulmonary —lipoprotein complexes lining the alveoli—include collectins such as surfactant proteins A and D, which bind motifs on microbial surfaces, aggregate pathogens, and facilitate their clearance while also modulating local immune responses.

Innate Immune System

Pathogen recognition

The initiates detection through pattern recognition receptors (PRRs), a class of germline-encoded proteins that identify conserved molecular signatures absent in healthy host cells. These receptors enable rapid, non-specific recognition of invading microbes and cellular damage, distinguishing from non-self without prior exposure. PRRs are expressed on immune and non-immune cells, including epithelial barriers and sentinel cells, and their triggers downstream inflammatory responses essential for host defense. Key families of PRRs include Toll-like receptors (TLRs), NOD-like receptors (NLRs), and RIG-I-like receptors (RLRs). Humans possess 10 functional TLRs (TLR1–TLR10), which are transmembrane proteins that detect extracellular and endosomal ligands; for instance, the discovery of TLRs as mammalian counterparts to the Toll protein highlighted their role in signaling adaptive immunity activation. NLRs, numbering 22 in humans, are cytoplasmic sensors that recognize intracellular threats and include subfamilies like NOD1, , and , which form upon activation. RLRs, comprising RIG-I, , and the regulatory LGP2, are RNA helicases specialized in detecting cytosolic viral nucleic acids. PRRs primarily target pathogen-associated molecular patterns (PAMPs), microbial structures essential for pathogen survival but absent in vertebrates. Examples include lipopolysaccharide (LPS), a component of Gram-negative bacterial outer membranes recognized by TLR4; , the structural protein of bacterial flagella detected by TLR5; and double-stranded RNA (dsRNA), a replication intermediate of many viruses sensed by TLR3 and RLRs. These interactions initiate tailored responses, such as NF-κB-mediated for bacterial PAMPs or type I production for viral ones. Beyond PAMPs, PRRs also detect damage-associated molecular patterns (DAMPs), endogenous molecules released during host cell injury, , or stress, which amplify immune alerts to sterile . Common DAMPs include high-mobility group box 1 () protein, extracellular ATP, and crystals, which bind receptors like TLR4, , and RIG-I to mimic infection signals. This dual recognition ensures responses to both infectious and non-infectious threats. Ligand engagement by PRRs activates intracellular signaling pathways, often converging on the transcription factor. For TLRs, this involves adaptor proteins like MyD88 or TRIF, leading to IκB kinase phosphorylation, NF-κB nuclear translocation, and transcription of proinflammatory cytokines such as TNF-α, IL-1β, and IL-6. NLRs and RLRs similarly promote NF-κB activation via RIPK2 or MAVS adaptors, respectively, resulting in cytokine release that recruits and activates innate immune cells for pathogen clearance.

Innate immune cells

The innate immune system relies on a diverse array of specialized cells that provide rapid, non-specific defense against pathogens through mechanisms such as , , and . These cells originate primarily from hematopoietic stem cells in the and are mobilized to sites of via , which guide their migration along concentration gradients to orchestrate early inflammatory responses. Phagocytes form the cornerstone of innate cellular immunity, engulfing and destroying through followed by lysosomal degradation. Neutrophils, the most abundant granulocytes, are short-lived cells with a lifespan of hours to days in circulation; they are rapidly produced in the during infection and recruited to tissues, where they contribute to formation by releasing antimicrobial contents after . Macrophages, derived from circulating monocytes that differentiate in tissues, serve as long-lived, resident capable of sustained pathogen clearance and initial to bridge innate and adaptive responses; their lifespan can extend from weeks to months depending on tissue environment and state. Dendritic cells, also monocyte-derived, excel in of pathogens and debris while migrating to lymph nodes to present antigens, thereby linking innate detection to adaptive . Natural killer (NK) cells provide cytotoxic defense against virus-infected and tumor cells without prior sensitization, comprising about 5-15% of circulating lymphocytes and produced in the with a lifespan of days to weeks. They induce target cell primarily through the release of perforin, which forms pores in the plasma membrane, and granzymes, serine proteases that enter cells to trigger caspase activation and programmed death. NK cells also mediate (ADCC) by recognizing antibody-coated targets via (FcγRIII) receptors, enhancing their perforin/granzyme-mediated killing. Other innate cells include , , and mast cells, which target larger parasites and modulate through granule release. , bone marrow-derived granulocytes with a lifespan of 8-12 days, specialize in combating helminth infections via and of cytotoxic granules containing major basic protein and peroxidase, which damage parasite membranes. and mast cells, both rich in and heparin-containing granules, promote upon IgE cross-linking or signals, releasing mediators that enhance and recruit other immune cells during allergic or parasitic responses; circulate briefly (hours to days) while tissue-resident mast cells persist for months.

Inflammatory processes

Inflammation represents a fundamental innate to tissue or , orchestrating a coordinated cascade to eliminate harmful agents and initiate repair. This process begins rapidly upon detection of damage-associated molecular patterns (DAMPs) or pathogen-associated molecular patterns (PAMPs) by resident immune cells, such as tissue macrophages and mast cells. The acute phase of inflammation unfolds in distinct stages, starting with vascular changes that facilitate immune cell access to the affected site. , primarily mediated by release from mast cells, increases blood flow, while elevated allows plasma proteins and fluid to extravasate, forming . These alterations, occurring within minutes, set the stage for cellular recruitment, where neutrophils marginate along vessel walls, adhere via selectins and , and migrate through the guided by chemotactic gradients. Key mediators drive these events, including cytokines such as interleukin-1 (IL-1) and tumor necrosis factor-alpha (TNF-α), which amplify endothelial activation and leukocyte adhesion; that direct cell trafficking; and prostaglandins derived from metabolism, which sustain and pain sensitization. Complement activation further amplifies inflammation through its classic pathway, triggered by antibody-bound complexes, and alternative pathway, initiated by spontaneous or microbial surfaces, both converging to generate anaphylatoxins like C3a and C5a that promote permeability and . The hallmark clinical manifestations of acute inflammation, known as the cardinal signs, include redness (rubor) from hyperemia, heat (calor) due to increased blood flow, swelling (tumor) from , pain (dolor) induced by mediators like and prostaglandins, and loss of function () resulting from tissue disruption. Resolution of acute inflammation is an active process regulated by anti-inflammatory signals, such as IL-10 produced by macrophages and regulatory T cells, which suppresses pro-inflammatory production and promotes tissue repair. Concurrently, neutrophils undergo , a that limits further tissue damage by containing cytotoxic contents, with apoptotic cells subsequently phagocytosed by macrophages in a non-phlogistic manner that reinforces IL-10 release and dampens the response.

Complement and humoral innate responses

The constitutes a critical component of humoral innate immunity, comprising a cascade of over 30 plasma and membrane-bound proteins that provide rapid, nonspecific defense against . Activated through three distinct pathways, it enhances , promotes , and directly lyses target cells, all while being tightly regulated to avoid host tissue damage. The classical pathway initiates when C1q binds to antibody-pathogen complexes or certain acute-phase proteins, activating the serine proteases C1r and C1s, which cleave C4 and C2 to form the C4b2a. The alternative pathway begins spontaneously through of C3 to C3(H2O), which binds factor B; factor D then cleaves factor B to generate the C3bBb, stabilized by on surfaces for amplification. The lectin pathway is triggered by mannose-binding lectin (MBL) or ficolins recognizing microbial carbohydrates, leading to activation of MASP-2, which cleaves C4 and C2 to produce the same C4b2a as in the classical pathway. All three pathways converge at C3 cleavage by their respective convertases, generating C3a (an anaphylatoxin) and C3b, which deposits on pathogens and forms the (C4b2a3b or C3bBb3b) to propagate downstream effects. Central functions of the complement system include opsonization, where C3b coats microbes to facilitate recognition and uptake by via complement receptors. is mediated by C5a, a cleavage product of C5 that attracts neutrophils and monocytes to infection sites, amplifying the inflammatory response initiated by earlier innate processes. occurs via the terminal pathway, in which C5b sequentially recruits C6, C7, C8, and multiple C9 molecules to assemble the membrane attack complex (C5b-9), forming transmembrane pores that disrupt pathogen membranes. Beyond complement proteins, other soluble humoral factors such as collectins and pentraxins contribute to innate defense. Collectins, including MBL, bind pathogen-associated molecular patterns to initiate the and promote opsonization. Pentraxins, a family of multimeric pattern recognition molecules, encompass short pentraxins like (CRP), which binds on damaged cells or microbes to activate the classical pathway via C1q, and the long pentraxin PTX3, produced at infection sites to opsonize fungi and regulate inflammation. To prevent autologous damage, the is regulated by soluble and membrane-bound inhibitors; notably, C1 esterase inhibitor (C1-INH) irreversibly binds and inactivates C1r, C1s, and MASP-2, thereby controlling classical and initiation while also modulating alternative pathway activity through interactions with C3b. Additional regulators like and C4b-binding protein further decay convertases and limit amplification on host cells.

Adaptive Immune System

Antigen recognition and specificity

The adaptive immune system achieves precise antigen recognition through specialized receptors expressed on lymphocytes, enabling specific identification of pathogens and foreign molecules. B cells express B cell receptors (BCRs), which are membrane-bound forms of immunoglobulins consisting of two heavy and two light chains that form an -binding site. T cells, in contrast, express T cell receptors (TCRs), which are heterodimeric proteins predominantly composed of α and β chains (αβ TCRs) in most T cells, or γ and δ chains (γδ TCRs) in a smaller subset. These receptors are non-covalently associated with invariant signaling molecules, such as /CD79b for BCRs and CD3 for TCRs, which facilitate intracellular upon antigen binding. The specificity of these receptors arises from the clonal selection theory, which posits that each lymphocyte clone expresses a unique receptor generated during development, and only those clones binding antigen undergo proliferation and differentiation. This theory, formulated by Frank Macfarlane Burnet, explains how the immune system selects and expands rare antigen-specific cells from a diverse pool without prior exposure to the antigen. Receptor diversity is primarily generated through V(D)J recombination, a somatic process in developing lymphocytes where variable (V), diversity (D, for some chains), and joining (J) gene segments are randomly rearranged to form the variable region of the receptor. Discovered by Susumu Tonegawa, this mechanism allows for the combinatorial assembly of gene segments, junctional flexibility during recombination, and additional processes like P-nucleotides and N-nucleotides to create immense variability. In humans, V(D)J recombination, combined with heavy-light chain pairing for BCRs and α-β chain pairing for TCRs, theoretically generates over 10^11 distinct receptor specificities, far exceeding the number of lymphocytes in the body and providing broad coverage against potential antigens. This diversity ensures that virtually any foreign epitope can be recognized, while the finite number of cells expresses a subset of these possibilities. Antigen engagement by these receptors typically requires presentation in the context of major histocompatibility complex (MHC) molecules for TCRs, linking recognition to the subsequent processing and display of antigens. To prevent autoimmunity, central tolerance mechanisms eliminate or inactivate self-reactive lymphocytes during development. In the thymus, developing T cells undergo negative selection, where those with high-affinity TCRs for self-peptides presented by MHC on thymic epithelial or dendritic cells are induced to undergo apoptosis, thus depleting potentially autoreactive clones. Similarly, in the bone marrow, immature B cells expressing BCRs that strongly bind self-antigens encounter negative selection through clonal deletion, receptor editing (secondary V(D)J recombination to alter specificity), or anergy, ensuring that mature B cells exiting the marrow are largely tolerant to self. These processes collectively shape the repertoire to favor foreign antigen recognition while minimizing self-reactivity.

Antigen presentation

Antigen presentation is the process by which cells display fragments of antigens on their surface using (MHC) molecules to alert T cells of the . This mechanism allows the adaptive to recognize and respond to intracellular pathogens, extracellular threats, and abnormal cells. MHC molecules bind processed peptides in specific intracellular compartments and transport them to the cell surface, where they are surveyed by T cell receptors. MHC class I molecules are expressed on nearly all nucleated cells and present endogenous antigens, such as those derived from cytosolic proteins including viral or tumor-associated peptides, to CD8+ T cells. In the classical cytosolic pathway, proteins in the cytoplasm are ubiquitinated and degraded by the proteasome into short peptides (typically 8–10 amino acids), which are then transported into the endoplasmic reticulum (ER) by the transporter associated with antigen processing (TAP). Within the ER, peptides are loaded onto nascent MHC class I molecules in the peptide-loading complex, involving chaperones like tapasin, calreticulin, and ERp57, before the complex traffics to the cell surface. MHC class II molecules are primarily expressed on professional antigen-presenting cells (APCs) such as dendritic cells, macrophages, and B cells, and they present exogenous antigens, like those from or engulfed by , to + T cells. In the endosomal pathway, internalized antigens are degraded in acidic endosomal/lysosomal compartments by proteases such as cathepsins, while αβ dimers associate with the invariant (Ii) in the ER to prevent premature peptide binding and direct the complex to MHC class II compartments (MIICs). The invariant is proteolytically cleaved, leaving the class II-associated invariant peptide (CLIP) in the peptide-binding groove; HLA-DM then facilitates CLIP removal and exchange for antigenic peptides (typically 13–25 ), enabling stable -peptide complexes to reach the plasma membrane. A specialized process called allows dendritic cells to present exogenous antigens on molecules, bridging innate and adaptive immunity by activating + T cells against extracellular pathogens or tumors without direct of the presenting cell. This occurs via two main pathways: the phagosome-to- route, where antigens escape endosomes to the cytosol for proteasomal degradation and TAP-dependent loading, and the vacuolar route, involving intra-phagosomal and TAP-independent peptide loading onto recycled . Dendritic cells are uniquely efficient at cross-presentation due to factors like Sec22b-mediated ER-phagosome fusion and low lysosomal degradation. Non-classical MHC class I molecules, such as and , present a restricted set of peptides and primarily regulate natural killer (NK) cell activity rather than conventional T cell responses. binds leader peptides from other HLA class I molecules and inhibits NK cells through interaction with CD94/NKG2A receptors, promoting in contexts like and transplantation. Similarly, presents diverse peptides and delivers inhibitory signals to NK cells via receptors like ILT2 and KIR2DL4, contributing to immune evasion in tumors and viral infections. These molecules are expressed on subsets of APCs and stressed cells, fine-tuning innate immunity alongside classical presentation pathways. The antigens presented via MHC molecules ultimately trigger cell-mediated immune responses by activating cytotoxic and helper T cells.

Cell-mediated immunity

Cell-mediated immunity refers to the adaptive immune response orchestrated primarily by T lymphocytes, which directly eliminate infected or abnormal cells and coordinate other immune functions without relying on antibodies. Unlike , this arm targets intracellular pathogens such as viruses and intracellular bacteria, as well as transformed cells like tumors, through cell-to-cell contact and signaling. T cells recognize antigens presented on (MHC) molecules by antigen-presenting cells, leading to their activation and differentiation into effector subsets. T cell activation follows a two-signal model, where the first signal is provided by the (TCR) binding to peptide-MHC complexes, and the second costimulatory signal is delivered via on T cells interacting with B7-1 () or B7-2 () on antigen-presenting cells. This prevents anergy and promotes proliferation, production, and differentiation; without it, T cells may become unresponsive or undergo . Cytotoxic CD8+ T cells, also known as killer T cells, directly lyse target cells through two main mechanisms: granule and death receptor signaling. In the granule pathway, they release perforin, which polymerizes to form pores in the target , allowing granzymes to enter and activate , leading to . Alternatively, CD8+ T cells induce via Fas ligand (FasL) binding to Fas receptors on targets, triggering the extrinsic death pathway through activation. These cells primarily target virally infected cells and tumor cells expressing altered antigens. Helper + T cells amplify and direct immune responses by secreting cytokines that modulate other cells. Th1 subsets produce interferon-gamma (IFN-γ), which activates macrophages to enhance and intracellular killing of pathogens. Th2 cells secrete interleukin-4 (IL-4), promoting differentiation and production in humoral responses. Th17 cells release IL-17, recruiting and activating neutrophils to combat extracellular bacteria and fungi at mucosal sites. Regulatory T cells (Tregs), a subset of + T cells expressing , maintain by suppressing excessive responses through secretion and cell contact. They produce IL-10 and transforming growth factor-beta (TGF-β), which inhibit proinflammatory production by effector T cells and antigen-presenting cells. This suppression prevents and dampens after clearance. Gamma delta (γδ) T cells represent a distinct lineage that provides rapid, innate-like responses at epithelial and mucosal barriers, independent of MHC restriction. They surveil for stress signals, such as phosphoantigens from infected or transformed cells, and respond quickly by producing cytokines like IFN-γ or directly lysing targets. In mucosal tissues, γδ T cells contribute to tissue homeostasis and early defense against pathogens before αβ T cell involvement. Helper CD4+ T cells also support antibody-mediated immunity by providing cytokines that enhance responses.

Antibody-mediated immunity

Antibody-mediated immunity, a key component of the adaptive , relies on B lymphocytes () to produce soluble antibodies that target and neutralize extracellular pathogens such as and viruses. Upon encountering an , naive B cells become activated and differentiate into antibody-secreting plasma cells, generating a humoral response that provides rapid and specific defense against infections. This process contrasts with by focusing on soluble effectors rather than direct cellular , enabling antibodies to circulate systemically and access diverse tissues. B cell activation occurs through two primary pathways: T cell-dependent (TD) and T cell-independent (). In the TD pathway, which predominates for protein antigens, internalize and present fragments to CD4+ T helper cells in secondary lymphoid organs, leading to cognate interactions that drive B cell proliferation and differentiation within germinal centers. These germinal centers facilitate class-switch recombination, transitioning antibody production from the initial IgM isotype to more specialized forms like IgG, IgA, or IgE, which confer enhanced effector functions tailored to the infection site. In contrast, the TI pathway activates directly via multivalent antigens, such as bacterial with repeating epitopes, bypassing T cell involvement and typically yielding short-lived IgM responses without class switching or extensive maturation. Antibodies, or immunoglobulins, exhibit a conserved Y-shaped structure composed of two identical heavy chains and two identical light chains, linked by bonds and non-covalent interactions, with a total molecular weight of approximately 150 kDa for the monomeric form. The antigen-binding fragment (Fab) regions, located at the tips of the Y arms, contain variable domains that confer specificity to the , while the crystallizable fragment (Fc) region at the base mediates interactions with immune cells and complement proteins. Antibodies exist in five main isotypes—IgA, IgD, IgE, IgG, and IgM—distinguished by their heavy chain constant regions, which determine their distribution and functions; for instance, IgM forms a pentameric structure for high-avidity early responses, whereas monomeric IgG predominates in serum and can cross the to provide neonatal immunity. The effector functions of antibodies enable multifaceted pathogen clearance. Neutralization occurs when antibodies bind to viral or toxin epitopes, sterically hindering attachment to host cells and preventing . Opsonization enhances by coating pathogens with antibodies, allowing Fc receptors on macrophages and neutrophils to recognize and engulf the targets efficiently. Complement activation is initiated via the classical pathway when the C1q component binds to the Fc region of IgM or IgG, triggering a cascade that forms membrane attack complexes to lyse or further opsonizes them with C3b. Additionally, (ADCC) recruits natural killer cells, which bind antibody-coated cells via Fcγ receptors and release perforin and granzymes to induce target . Following activation, B cells differentiate into plasma cells, long-lived effector cells residing primarily in the that secrete thousands of antibodies per second to sustain . During the TD response in germinal centers, affinity maturation refines antibody quality through , a process where activation-induced cytidine deaminase introduces point into the variable regions of immunoglobulin genes at rates up to 10^6 times higher than baseline. Subsequent selection favors B cells with mutations enhancing affinity, leading to progressively higher-avidity antibodies over iterative cycles of mutation and competition for and survival signals. This maturation not only amplifies protective efficacy but also generates memory B cells derived from activated B cells, enabling faster and stronger responses upon re-exposure.

Immunological memory

Immunological memory refers to the adaptive immune system's ability to retain information about previously encountered pathogens, allowing for accelerated and amplified responses during subsequent exposures. This phenomenon is orchestrated by long-lived memory B cells and memory T cells, which arise from the primary and persist in lymphoid and non-lymphoid tissues for years or even lifetimes. Unlike the , which lacks memory, these adaptive memory cells enable protection against reinfection, forming the basis for immunological . Memory B cells, often marked by CD27 expression, differentiate through germinal center reactions involving and affinity maturation, leading to high-affinity production upon reactivation. They include subsets analogous to T cell memory, with some recirculating through lymphoid organs and others residing in tissues for localized responses. Memory T cells, conversely, are heterogeneous and classified into central memory T cells (T_CM), which home to lymph nodes via CCR7 and CD62L expression for sustained proliferation potential, and effector memory T cells (T_EM), which patrol peripheral tissues lacking these homing receptors to provide immediate effector functions like release. Both subsets are maintained by s such as IL-7 and IL-15, ensuring longevity without ongoing stimulation. The primary immune response exhibits a lag phase of approximately 4-7 days before detectable production, dominated by IgM with lower affinity and magnitude, peaking around 7-10 days post-exposure. In contrast, secondary responses triggered by memory cells show a markedly reduced lag of 1-3 days, transitioning rapidly to high-affinity IgG production with titers 100- to 1,000-fold higher and more sustained. This enhanced kinetics and scale stem from the pre-existing clonal expansion of memory cells, minimizing the need for de novo activation. Epigenetic modifications, including , histone acetylation, and , underpin memory cell maintenance by locking in stable profiles that facilitate swift reactivation. For instance, in memory T cells, these changes poise loci for rapid transcription of effector genes like those encoding cytokines, independent of . Similar epigenetic programming in memory B cells supports their quiescent state while priming for differentiation into plasma cells. Immunological memory is not indefinite; waning over time, particularly in antibody levels, can reduce protection, as observed in vaccines where humoral responses decline months post-immunization. Booster vaccinations counteract this by reinvigorating cells, eliciting responses comparable to or exceeding secondary exposures and enhancing long-term against evolving pathogens. In immunodeficiencies, impaired memory formation leads to diminished secondary responses and increased susceptibility to recurrent infections.

Regulation and Homeostasis

Hormonal influences

The endocrine system exerts profound bidirectional influences on the immune system, with hormones modulating immune cell function, production, and inflammatory responses, while immune signals in turn regulate secretion. This interplay ensures but can also contribute to immune dysregulation under or hormonal imbalance. Key hormones from the hypothalamic-pituitary-adrenal (HPA) axis, gonads, and gland play central roles in this regulation. Stress hormones, particularly like , suppress by inhibiting the NF-κB, which reduces the expression of pro-inflammatory cytokines such as IL-1, IL-6, and TNF-α. This anti-inflammatory action occurs through glucocorticoid receptor-mediated repression of activity in immune cells like macrophages and T lymphocytes, thereby limiting excessive immune responses during stress. Catecholamines, including epinephrine and norepinephrine released during acute stress, enhance natural killer (NK) cell activity by promoting their redistribution from marginal to circulating pools, increasing NK cell numbers and against virally infected or tumor cells via β-adrenergic receptor signaling. Sex hormones exhibit sexually dimorphic effects on immunity, with generally enhancing by promoting differentiation, production, and Th2 responses, while testosterone favors by supporting Th1 responses and suppressing excessive inflammation. These effects contribute to observed sex differences in prevalence, where females show stronger antibody-mediated responses. Fluctuations during the further modulate immunity, with higher levels in the boosting titers and NK cell activity, whereas progesterone dominance in the dampens pro-inflammatory responses to maintain tolerance. Thyroid hormones, (T3) and thyroxine (T4), regulate proliferation and differentiation by binding to thyroid hormone receptors on T and B cells, enhancing mitogen-induced proliferation and secretion in euthyroid states. amplifies T and B cell responses, increasing IgG production and T cell activation, while impairs these processes, leading to reduced immune competence. This modulation occurs via genomic effects on and non-genomic pathways influencing . The immune-endocrine axis is bidirectional, with pro-inflammatory cytokines like IL-1, IL-6, and TNF-α stimulating the HPA axis to increase release, thereby providing to resolve . This cytokine-driven activation of (CRH) and (ACTH) secretion helps coordinate systemic responses to or . Nutritional factors, such as adequate intake of precursors for synthesis, can interact with this axis to support balanced immune regulation.

Nutritional and environmental factors

Nutritional and environmental factors play a critical role in maintaining immune by modulating innate and adaptive responses, influencing production, and supporting microbial balance in the host. Deficiencies or excesses in these factors can disrupt immune regulation, leading to heightened or impaired defenses against pathogens. Key elements include vitamins derived from diet and , sleep patterns, physical activity levels, and the gut , each interacting with immune cells to promote resilience or vulnerability. Vitamin D, primarily synthesized in the skin upon exposure to ultraviolet B from , acts as a key regulator of immune function through its active form, 1,25-dihydroxyvitamin D3, which binds to the (VDR) expressed on various immune cells such as macrophages, dendritic cells, and T lymphocytes. This binding enhances the expression of , notably cathelicidin (LL-37), which exhibits broad-spectrum activity against , viruses, and fungi by disrupting microbial membranes and promoting in infected cells. VDR signaling also modulates T-cell differentiation, favoring regulatory T cells to dampen excessive while bolstering innate defenses. Insufficient levels, common in populations with limited sun exposure, correlate with reduced cathelicidin production and increased susceptibility to respiratory infections. Adequate , typically 7-9 hours per night for adults, is essential for balancing pro- and cytokines, supporting T-cell proliferation, and maintaining natural killer (NK) cell activity. During , the immune system undergoes restorative processes, including the release of and , which enhance production and phagocytic function. Chronic disrupts this balance by elevating proinflammatory cytokines like IL-6 and TNF-α, while suppressing IL-10, thereby increasing susceptibility to infections and exacerbating inflammatory conditions. Experimental studies show that even partial sleep restriction over several nights impairs leukocyte function and heightens vulnerability to viral pathogens. Moderate exercise, such as 30-60 minutes of aerobic activity most days, enhances immune surveillance by increasing circulating NK cells and promoting IL-6 release from contracting muscles, which acts as a to coordinate responses and improve metabolic health. This activity facilitates leukocyte trafficking, with enhanced migration of immune cells to tissues via upregulated chemokine receptors like on CD8+ T and NK cells. In contrast, excessive or prolonged intense exercise can suppress immune function temporarily, reducing NK cell cytotoxicity and increasing , which may elevate risk in athletes. Regular moderate regimens, however, cumulatively strengthen adaptive immunity through improved lymph flow and reduced chronic inflammation. The gut microbiome, comprising trillions of commensal bacteria, trains the immune system by producing (SCFAs) such as butyrate, propionate, and from , which signal through G-protein-coupled receptors on immune cells to promote regulatory T-cell differentiation and IgA production by plasma cells in the gut mucosa. These SCFAs enhance epithelial barrier integrity and modulate function, fostering tolerance to harmless antigens while priming defenses against pathogens. , characterized by reduced microbial diversity often linked to poor diet or antibiotics, diminishes SCFA levels and is associated with heightened via increased Th17 cell activity and leaky gut permeability, as evidenced in post-2020 studies on and metabolic disorders. Restoring microbiome balance through fiber-rich diets supports immune across distant sites like the lungs and skin.

Tissue repair mechanisms

Tissue repair mechanisms in the immune system are integral to , transitioning from the inflammatory phase to orchestrated processes that restore tissue integrity and function. Following initial , where immune cells clear debris and pathogens, repair begins with , involving platelet aggregation to form a clot that stabilizes the and provides a scaffold for cellular infiltration. Platelets release growth factors such as (PDGF) and transforming growth factor-beta (TGF-β), which recruit fibroblasts and endothelial cells to initiate subsequent phases. The inflammatory phase overlaps with early repair, dominated by macrophages that shift from pro-inflammatory M1 to anti-inflammatory M2 phenotypes to promote resolution and tissue remodeling. M2 macrophages secrete anti-inflammatory cytokines like interleukin-10 (IL-10) and TGF-β, facilitating debris clearance while suppressing excessive inflammation to prevent chronic damage. Regulatory T cells (Tregs) further modulate this process by inhibiting fibrotic responses through IL-10 and TGF-β production, ensuring balanced repair without overproduction of extracellular matrix. In the proliferation phase, immune-derived signals drive activation and , with macrophages and T cells upregulating (VEGF) to stimulate endothelial cell and new vessel formation essential for nutrient delivery. , recruited by immune signals, deposit and other matrix components to form , supported by mesenchymal stem cells (MSCs) from that differentiate into fibroblasts and secrete paracrine factors enhancing repair. MSCs interact with macrophages to polarize them toward states, amplifying and pro-regenerative effects. The remodeling phase involves matrix metalloproteinases (MMPs) from immune cells and fibroblasts to reorganize collagen, replacing type III with stronger for tensile strength, a process that can last months. Tregs limit excessive during this stage by suppressing differentiation. When repair mechanisms fail, mammalian tissues often result in scarring due to dysregulated immune responses, such as persistent M1 activity leading to , whereas lower vertebrates like salamanders achieve scarless regeneration through rapid M2 polarization and Treg-mediated suppression of . This contrast highlights the immune system's pivotal role in determining regenerative outcomes.

Disorders of Immunity

Primary and secondary immunodeficiencies

Primary immunodeficiencies are a group of congenital disorders caused by genetic defects that impair the development or function of immune cells, leading to increased susceptibility to infections. These conditions arise from mutations in over 550 genes, with more than 555 distinct disorders identified as of 2024. The incidence of primary immunodeficiencies is estimated at approximately 1 in 1200 individuals as of 2025. Common examples include (SCID), often resulting from (ADA) deficiency, which disrupts development and function, and , caused by mutations in the BTK gene that prevent B-cell maturation and antibody production. In contrast, secondary immunodeficiencies are acquired conditions that compromise immune function through external factors, rather than inherent genetic flaws. These include infection leading to acquired immunodeficiency syndrome (AIDS), which progressively depletes T cells and impairs overall immune surveillance; , which exacerbates immune impairment by limiting nutrient availability for immune cell production and function; and treatments such as , which suppress activity and reduce counts in patients with malignancies. Both primary and secondary immunodeficiencies manifest with recurrent, severe infections—such as , , and skin infections—as well as in affected children, characterized by poor weight gain and growth delays due to chronic illness and . Management of these disorders focuses on preventing infections and restoring immune competence, particularly for primary forms. Immunoglobulin replacement therapy provides exogenous antibodies to compensate for deficiencies in , while (HSCT) replaces defective immune cells with healthy donor cells. represents a targeted approach for specific primary immunodeficiencies, such as ADA-SCID; Strimvelis, an lentiviral vector-based therapy that corrects the ADA in autologous hematopoietic stem cells, was approved in 2016 and has shown sustained immune reconstitution in treated patients, with marketing authorization transferred to in 2024 to ensure continued availability. For secondary immunodeficiencies, treatment primarily addresses the underlying cause, such as antiretroviral therapy for or nutritional support for , alongside supportive measures like prophylactic antibiotics.

Autoimmune diseases

Autoimmune diseases arise when the immune system erroneously targets and damages the body's own tissues and cells, leading to chronic inflammation and organ dysfunction. These conditions affect approximately 5-10% of the global population, with estimates indicating a combined prevalence of around 10% in developed countries, though exact figures vary by region and diagnostic criteria. Notably, about 78% of individuals with autoimmune diseases are female, a disparity linked to hormonal influences such as , which modulates immune responses by promoting B-cell activation and production while enhancing T-cell differentiation toward pro-inflammatory phenotypes. This sex bias underscores the interplay between , hormones, and environmental triggers in disease susceptibility. The of autoimmune diseases fundamentally involves the breakdown of immune self-tolerance, the mechanisms that normally prevent immune responses against self-antigens. Central tolerance occurs in the and , where autoreactive T and B cells are deleted or rendered anergic during development; failures here, such as defective negative selection, allow self-reactive lymphocytes to enter circulation. mechanisms, including anergy (functional inactivation of autoreactive cells), deletion, and suppression by regulatory T cells (Tregs), further maintain in mature immune cells; defects in Treg function or number, often due to genetic mutations in or IL-2 signaling, impair this suppression and contribute to . Primary immunodeficiencies can exacerbate this risk by increasing susceptibility to infections, which may trigger or perpetuate autoimmune responses through chronic immune activation. Key mechanisms driving tolerance breakdown include molecular mimicry, where foreign antigens (e.g., from pathogens) share structural similarities with self-antigens, leading to cross-reactive immune attacks; this is implicated in initiating following infections. Epitope spreading occurs when initial immune responses to a self-antigen expand to unrelated s on the same or different autoantigens, amplifying tissue damage during chronic inflammation. Genetic factors also play a pivotal role, with (HLA) alleles conferring susceptibility; for instance, is strongly associated with (RA), increasing risk by facilitating presentation of arthritogenic peptides to autoreactive T cells and promoting production. Representative examples illustrate these processes. In type 1 diabetes, autoreactive T cells infiltrate pancreatic islets, leading to beta-cell destruction and insulin deficiency; molecular mimicry with viral proteins and epitope spreading to islet autoantigens like insulin and GAD65 drive the progressive loss of glucose homeostasis. Multiple sclerosis (MS) involves T-cell and B-cell mediated demyelination in the central nervous system, where breakdown of blood-brain barrier tolerance allows cross-reactive responses to myelin basic protein, resulting in axonal damage and neurological deficits. Systemic lupus erythematosus (SLE) features production of antinuclear antibodies (ANAs) that form immune complexes, causing widespread inflammation in skin, joints, and kidneys; central and peripheral tolerance failures enable hyperactive B cells to generate these autoantibodies against nuclear components like DNA and histones.

Allergic and hypersensitivity reactions

Allergic and hypersensitivity reactions represent exaggerated immune responses to otherwise harmless antigens, such as , proteins, or environmental allergens, leading to tissue damage and clinical symptoms. These reactions are primarily mediated by the and can range from mild discomfort to life-threatening conditions like . Unlike protective immunity, hypersensitivity arises when the immune system misinterprets benign substances as threats, often involving specific or T-cell mechanisms that amplify . The provides a foundational framework for understanding these reactions, categorizing them into four types based on the underlying immunological processes. Type I hypersensitivity, also known as immediate hypersensitivity, is IgE-mediated and occurs rapidly upon re-exposure to an . In this process, allergen-specific IgE antibodies bind to high-affinity receptors (FcεRI) on the surface of mast cells and ; subsequent allergen cross-linking triggers mast cell , releasing preformed mediators like , as well as newly synthesized leukotrienes and prostaglandins. induces , increased , smooth muscle contraction, and mucus secretion, resulting in symptoms such as urticaria, , or . A classic example is peanut-induced , where systemic can cause and airway obstruction within minutes. Type II hypersensitivity involves antibodies (typically IgG or IgM) directed against antigens on cell surfaces or components, leading to . The antibodies bind to target cells, activating complement or recruiting natural killer cells and macrophages via (ADCC), which results in cell or . This type is exemplified by , where antibodies target antigens, causing their destruction in the or via complement-mediated and subsequent . Another instance is transfusion reactions, where mismatched blood group antibodies attack donor erythrocytes. Type III hypersensitivity arises from the deposition of immune complexes—formed by soluble antigens and IgG or IgM antibodies—in tissues, particularly in vessel walls or synovial spaces. These complexes activate complement, attracting neutrophils that release lysosomal enzymes and , causing local and tissue injury. In systemic lupus erythematosus (SLE), immune complexes contribute to through deposition in synovium, leading to complement and chronic . Serum sickness, often triggered by drugs like penicillin, similarly involves circulating complexes that deposit in kidneys and , producing fever, , and arthralgias. Type IV hypersensitivity, or delayed-type hypersensitivity, is mediated by T cells rather than antibodies and develops over 48–72 hours. Antigen-presenting cells process and present the to + T helper cells, which differentiate into effector subsets (e.g., Th1 or Th17) that release cytokines like IFN-γ and TNF-α, recruiting and activating macrophages. This leads to localized inflammation and tissue damage, as seen in from allergens like or , where sensitized T cells infiltrate the skin, causing eczematous lesions. Type IV reactions can overlap briefly with chronic inflammation in persistent exposures but remain distinct in their cell-mediated nature. Atopy refers to a genetic predisposition to develop IgE-mediated hypersensitivity reactions, characterized by an imbalance in immune responses favoring Th2 cells over Th1 or Th17 pathways. Individuals with atopy exhibit heightened production of Th2 cytokines such as IL-4, IL-5, and IL-13, which promote B-cell class switching to IgE and eosinophil recruitment, skewing the immune environment toward allergic inflammation. This predisposition is polygenic, with variants in genes like FLG (filaggrin) and IL4RA increasing susceptibility, often manifesting as the "atopic march" from eczema to allergic rhinitis and asthma. Environmental factors, including early-life exposures, interact with this genetic background to exacerbate Th2 skewing. Common manifestations of hypersensitivity include , driven by bronchial hyperreactivity where inhaled allergens provoke exaggerated airway contraction and hypersecretion via IgE-dependent activation. In , Th2-skewed responses lead to eosinophilic infiltration and chronic airway remodeling, with symptoms like wheezing and dyspnea triggered by or dust mites. Food allergies, predominantly Type I, affect approximately 5–8% of children and involve rapid IgE-mediated reactions to proteins in , , eggs, or , potentially causing oral itching, gastrointestinal distress, or . The global prevalence of allergic diseases has risen significantly, now impacting 10–30% of children in developed regions, attributed to factors like the and urbanization reducing microbial diversity.

Chronic inflammatory conditions

Chronic inflammatory conditions represent a state of prolonged, low-grade immune that persists beyond the resolution of an initial insult, leading to tissue damage and . Unlike acute , which is typically self-limiting and protective, chronic involves sustained recruitment of immune cells such as macrophages and lymphocytes, resulting in the release of pro-inflammatory mediators that perpetuate the response. This dysregulation can arise from unresolved acute , where failure to clear pathogens or debris leads to ongoing signaling through receptors. In , chronic drives the formation of arterial plaques through the accumulation of lipid-laden macrophages and foam cells in the vessel wall, promoting and plaque instability. (IBD), encompassing and , features persistent mucosal mediated by the , which activates caspase-1 to process pro-IL-1β and induce in epithelial cells, exacerbating barrier dysfunction. These conditions highlight how immune dysregulation can target specific tissues, with involving adaptive responses to oxidized and IBD linked to dysbiosis-induced innate signaling. Key mechanisms include cytokine storms characterized by elevated levels of interleukin-6 (IL-6) and tumor necrosis factor (TNF), which amplify immune cell recruitment and survival while suppressing pathways. activation plays a central role, as these cells respond to TNF and IL-6 by proliferating and depositing , contributing to in chronic settings. reactions may occasionally trigger such persistence, though chronic forms are distinguished by their indolent progression. Idiopathic chronic inflammatory conditions, where no specific trigger is identified, include , marked by non-caseating granulomas formed through T helper 1 cell-dominated responses involving IFN-γ production by alveolar macrophages. presents with systemic inflammation, high levels, and , driven by innate immune hyperactivity without evident . Metabolic links further underscore chronic inflammation's breadth, as obesity induces low-grade inflammation via adipokines like and , which promote infiltration into and systemic elevation. Post-2020 observations in reveal persistent , with elevated IL-6 and TNF correlating to and organ sequelae, potentially due to viral remnants sustaining .

Medical Applications

Immunosuppressive therapies

Immunosuppressive therapies encompass a range of pharmacological agents and interventions designed to modulate or suppress excessive immune responses, primarily to prevent organ transplant rejection or manage autoimmune diseases. These therapies target key components of the immune system, such as T-cell activation, production, and B-cell function, while balancing the risk of over-suppression that could lead to infections or malignancies. Calcineurin inhibitors, including cyclosporine and , form a of maintenance in solid . These agents bind to intracellular immunophilins— for cyclosporine and FK-binding protein for —forming complexes that inhibit the phosphatase activity of . This blockade prevents the dephosphorylation and nuclear translocation of nuclear factor of activated T cells (NFAT), thereby disrupting the transcription of interleukin-2 (IL-2) and other cytokines essential for T-cell proliferation and . In clinical practice, cyclosporine and significantly reduce acute rejection rates in , liver, and heart transplants, with often preferred due to its potency and lower incidence of cosmetic side effects like . Corticosteroids, such as prednisone, exert broad immunosuppressive effects by binding to glucocorticoid receptors, which translocate to the nucleus and interact with transcription factors like nuclear factor kappa B (NF-κB). This interaction, known as transrepression, inhibits NF-κB's ability to promote pro-inflammatory gene expression, including cytokines such as IL-1, IL-6, and TNF-α. Prednisone is commonly used in induction regimens for transplant recipients and as a first-line agent in autoimmune conditions like rheumatoid arthritis and systemic lupus erythematosus, often in combination with other immunosuppressants to minimize doses and side effects. Monoclonal antibodies provide targeted by depleting specific immune cell populations or neutralizing key cytokines. Rituximab, a chimeric anti-CD20 , induces B-cell depletion through mechanisms including (ADCC), (CDC), and direct of CD20-positive B cells, thereby reducing production that contributes to rejection or . It is employed off-label in transplant settings for antibody-mediated rejection and in autoimmune diseases such as . Infliximab, a chimeric anti-TNF-α , neutralizes soluble and membrane-bound TNF-α, preventing its binding to receptors and subsequent activation of inflammatory cascades; this is particularly effective in autoimmune disorders like and , though its use in transplantation is more limited to cases of refractory rejection. These therapies are primarily applied to prevent allograft rejection in , where regimens combining inhibitors, corticosteroids, and sometimes monoclonal antibodies achieve graft survival rates exceeding 90% at one year for transplants. In , they mitigate tissue damage from self-reactive immune responses, as seen with in . However, a major side effect across all classes is heightened susceptibility to infections due to impaired pathogen clearance; for instance, inhibitors and corticosteroids increase the risk of opportunistic infections like and pneumonia by 2- to 5-fold in transplant patients. Other complications include from inhibitors and metabolic disturbances from corticosteroids, necessitating vigilant monitoring and prophylactic antimicrobials.

Immunostimulatory approaches

Immunostimulatory approaches encompass therapeutic strategies designed to augment the immune system's capacity to recognize and combat pathogens or aberrant cells, often by directly activating innate and adaptive responses. These methods contrast with immunosuppressive therapies by promoting immune activation rather than inhibition, and they play a critical role in treating infections, enhancing efficacy, and supporting antitumor immunity. Key modalities include administration, adjuvant use, modulation, and nutritional interventions that bolster overall immune competence. Cytokine therapy leverages the administration of naturally occurring signaling molecules to amplify immune effector functions. Interferon-alpha (IFN-α), for instance, exhibits both antiviral and immunomodulatory properties, making it a cornerstone treatment for chronic . Pegylated IFN-α is used as an alternative therapy for chronic in select patients, where it induces sustained viral suppression in a subset of patients by enhancing cytotoxic T-cell responses and inhibiting . Similarly, high-dose interleukin-2 (IL-2) has been approved for advanced , where it promotes the expansion and activation of cytotoxic T cells and natural killer cells, leading to durable complete or partial tumor regressions in approximately 5-10% of patients despite significant . These therapies highlight cytokines' potential to redirect immune , though their use is tempered by side effects such as flu-like symptoms for IFN-α and vascular leak syndrome for IL-2. Adjuvants are compounds incorporated into vaccines or immunotherapies to potentiate antigen-specific responses by stimulating innate immunity. Aluminum salts, such as , represent the most widely used adjuvants and primarily elicit a Th2-biased humoral response by recruiting neutrophils, , and dendritic cells to the injection site, thereby prolonging and enhancing production. In contrast, MF59, an oil-in-water of , more broadly activates innate signals by inducing the release of and cytokines like ATP, which recruit monocytes and promote a mixed Th1/Th2 response, resulting in superior cellular and compared to in certain vaccines. These mechanisms underscore adjuvants' role in bridging innate danger sensing to adaptive memory formation without directly targeting specific pathogens. Immune checkpoint inhibitors briefly exemplify targeted immunostimulation by relieving inhibitory signals on T cells. blockers, such as , bind to the programmed death-1 receptor on activated T cells, preventing its interaction with PD-L1 on tumor cells and thereby reinvigorating exhausted antitumor responses. Approved for multiple malignancies, has demonstrated objective response rates of 20-40% in PD-L1-positive advanced solid tumors, establishing it as a pivotal tool in . Probiotics and immunonutrition offer non-pharmacological avenues for general immune enhancement by modulating the gut and nutrient status. , live beneficial microorganisms, regulate immune by suppressing pro-inflammatory Th2 responses and bolstering Th1-mediated defenses, potentially reducing infection susceptibility through improved mucosal barrier function and balance. Immunonutrition, involving targeted supplementation with alongside nutrients like or omega-3 fatty acids, further amplifies activity and systemic immunity, particularly in vulnerable populations such as the elderly or perioperative patients, where it accelerates recovery and mitigates inflammatory overload.

Vaccination strategies

Vaccination strategies harness the immune system's ability to develop against pathogens by introducing safe antigens that trigger adaptive responses, including production and T-cell activation, without causing illness. This process establishes long-term protection through immunological , as discussed in foundational texts. Various types achieve this by presenting antigens in different forms, tailored to balance , , and ease of administration. Live-attenuated vaccines use weakened forms of the to replicate mildly in the body, closely mimicking natural and often inducing robust, long-lasting immunity with fewer doses. Examples include the measles-mumps-rubella (, which protects against three viral diseases and is administered in two doses during childhood. Inactivated vaccines, in contrast, contain killed that cannot replicate, providing safer options for immunocompromised individuals but typically requiring boosters for sustained protection; the inactivated (IPV), given as a series of shots, has nearly eradicated in vaccinated populations. Subunit vaccines target specific components, such as proteins, to elicit targeted responses without whole- risks; the human papillomavirus (HPV) vaccine, like Gardasil 9, uses virus-like particles from HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58 to prevent cervical and other cancers. Emerging mRNA vaccines deliver genetic instructions for cells to produce antigens, enabling rapid production and strong immune activation; the Pfizer-BioNTech (BNT162b2), approved in 2020, demonstrated 95% efficacy against symptomatic in initial trials among individuals aged 16 and older. Achieving is a key goal of strategies, where sufficient coverage prevents to vulnerable groups. The threshold depends on the pathogen's (R₀), calculated as 1 - (1/R₀), representing the average secondary infections from one case in a susceptible . For , with an R₀ of 12–18, approximately 95% coverage is required to interrupt transmission, protecting unvaccinated individuals through reduced community spread. Vaccine development follows rigorous phases to ensure safety and . Preclinical studies in labs and animals assess design and initial safety, followed by an (IND) application to the FDA for human trials. Phase I trials involve 20–100 volunteers to evaluate safety and dosage. Phase II expands to hundreds, testing and side effects across doses. Phase III engages thousands in randomized, placebo-controlled studies to confirm effectiveness against disease. Post-approval, phase IV monitors long-term effects. Adjuvants, such as aluminum salts or oil-in-water emulsions like MF59, are incorporated to enhance , boost and T-cell responses, reduce required doses, and improve in vulnerable populations like the elderly. Despite successes, vaccination faces challenges from anti-vaccine movements, which spread misinformation and erode trust, leading to hesitancy and outbreaks; the World Health Organization identified vaccine hesitancy as a top global health threat in 2019. Emerging pathogen variants, such as SARS-CoV-2 Omicron sublineages, can partially evade vaccine-induced antibodies, necessitating booster updates to maintain protection levels. For instance, while the original Pfizer mRNA vaccine showed 95% efficacy against early COVID-19 strains, effectiveness against variants like Delta was around 90% for severe disease prevention, underscoring the need for adaptive strategies.

Cancer immunotherapy

Cancer immunotherapy encompasses a range of strategies that leverage the immune system to target and eliminate malignant cells, transforming previously intractable tumors into manageable conditions through activation of adaptive and innate immune responses. These approaches address the immune system's natural capacity to recognize and destroy cancer cells, which is often suppressed in the , and have led to durable remissions in subsets of patients with advanced disease. Central to these therapies are tumor antigens, which serve as recognition targets for immune effectors. Neoantigens arise from tumor-specific somatic mutations, such as point mutations or insertions/deletions, creating novel peptides presented on (MHC) molecules to T cells; these are highly immunogenic due to their absence in normal tissues, making them ideal for personalized vaccines and T cell therapies. Cancer-testis antigens, conversely, are proteins normally restricted to germ cells and placental tissues but aberrantly expressed in various cancers due to epigenetic dysregulation, such as hypomethylation of promoter regions; examples include NY-ESO-1 and MAGE-A family members, which elicit + T cell responses while minimizing risks. Tumors evade immune detection through multiple mechanisms that disrupt and T cell function. Upregulation of programmed death-ligand 1 () on tumor cells, often induced by interferon-gamma from infiltrating T cells or oncogenic signaling via pathways like PI3K/AKT, binds PD-1 on T cells to inhibit activation and promote exhaustion, allowing tumor persistence. Loss of expression, achieved through genetic alterations (e.g., mutations in β2-microglobulin or TAP genes) or epigenetic silencing, prevents neoantigen presentation to cytotoxic T cells, rendering tumors invisible to ; this occurs in approximately 30-40% of tumors and up to 90% in certain other cancers, such as colorectal , and contributes to resistance against T cell-based therapies. Checkpoint blockade inhibitors counteract evasion by restoring T cell activity. , a targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), was approved by the FDA in 2011 for unresectable or metastatic , blocking CTLA-4's inhibitory role in early T cell priming within lymph nodes; clinical trials demonstrated objective response rates of 10-15%, with durable responses in 20-40% of responders leading to long-term survival benefits. Chimeric antigen receptor (CAR) T cell therapies engineer patient T cells to express synthetic receptors targeting tumor s, building on principles of . Axicabtagene ciloleucel (Yescarta), a CD19-directed CAR-T product, received FDA approval in 2017 for relapsed or large after at least two prior therapies; in the pivotal ZUMA-1 trial, it achieved an overall response rate of 82% and complete remission in 54% of patients, with many maintaining responses beyond two years. Bispecific antibodies engage immune cells directly against tumors by simultaneously binding tumor antigens and immune receptors. Blinatumomab (Blincyto), a CD19/CD3 bispecific T cell engager, was granted accelerated FDA approval in 2014 and full approval in 2017 for relapsed or refractory B-cell precursor ; it redirects T cells to lyse + tumor cells, yielding complete remission rates of 40-45% in heavily pretreated adults.

Evolutionary Perspectives

Origins and development in vertebrates

The immune system in vertebrates exhibits remarkable diversity, with adaptive immunity emerging independently in jawless and jawed lineages. In jawless vertebrates, such as lampreys and , adaptive immune recognition relies on variable lymphocyte receptors (VLRs) rather than immunoglobulins (Igs) or T-cell receptors (TCRs). These VLRs are (LRR)-based proteins that undergo somatic diversification through a RAG-independent mechanism involving gene conversion with flanking LRR cassettes, enabling antigen-specific responses with affinities comparable to those of mammalian antibodies. Lymphocytes expressing VLRA and VLRB mature in specialized tissues like the supraneural body and typhlosole, analogous to lymphoid organs in jawed vertebrates. The transition to jawed vertebrates (gnathostomes), which appeared around 500 million years ago, introduced a fundamentally different adaptive immune system based on RAG1 and RAG2 genes that mediate V(D)J recombination. This process assembles diverse variable (V), diversity (D), and joining (J) gene segments to generate a vast repertoire of Igs and TCRs, allowing for precise antigen recognition and memory. IgM represents the primordial antibody class in gnathostomes, with its heavy- and light-chain genes organized in clusters in early-diverging groups like cartilaginous fish, facilitating initial humoral responses before the evolution of class-switched isotypes. Lymphoid organs in vertebrates evolved to support development and maturation, with the and playing central roles. The originates from epithelial buds at the base of the arches, specifically from the ectoderm-endoderm junction in the pharyngeal pouches of , where it differentiates into a site for T-cell shortly after hatching. In teleosts like , thymic buds form above the first few arches, with and vascular elements immigrating from to establish the organ's structure. The , emerging as the earliest secondary lymphoid organ in gnathostomes, features a white pulp region for adaptive responses, evolving from basic B-cell zones around arterioles in cartilaginous to more segregated T- and B-cell compartments in bony and higher vertebrates. This diversification of the vertebrate immune system was driven by co-evolution with pathogens, where selective pressures from diverse microbial threats promoted the expansion of receptor repertoires and organ complexity over hundreds of millions of years. In gnathostomes, the integration of innate and adaptive components enhanced defense against evolving pathogens, fostering genetic mechanisms like V(D)J recombination to generate variability far exceeding that of germline-encoded innate receptors.

Invertebrate immune mechanisms

Invertebrates lack an and rely exclusively on innate immune mechanisms to defend against pathogens and parasites. These responses are germline-encoded and evolutionarily ancient, providing rapid but non-specific protection through cellular and humoral pathways. Hemocytes, the circulating immune cells in many such as and crustaceans, play a central role in cellular immunity by recognizing and engulfing invading microbes via phagocytosis.00128-6) In like the mosquito Anopheles gambiae, phagocytic hemocytes actively internalize and parasites, initiating downstream processes. This mechanism is modulated by signaling molecules, such as in lepidopteran , which enhances hemocyte phagocytic activity through D1-like receptors. Humoral immunity in invertebrates often involves the prophenoloxidase (proPO) system, which activates to produce for encapsulation and killing. Phenoloxidase enzymes, activated by a cascade of serine proteases in response to pathogen-associated molecular patterns, oxidize into quinones that polymerize into , trapping and immobilizing invaders.00108-7) This melanization process is prominent in arthropods, where it contributes to and defense against fungi, , and parasites, as seen in like the greater wax moth . (RNAi) serves as a key antiviral mechanism in both and animal by targeting viral genomes. Animal also employ and for intracellular control.01029-5) degrades engulfed pathogens within hemocytes or other cells, promoting survival against and viruses in models like the fruit fly and nematode . , meanwhile, eliminates infected cells to limit spread, balancing with to maintain tissue during . Social insects extend innate immunity through collective behaviors known as social immunity, where colony members cooperate to reduce disease transmission. In ant colonies, such as those of the Camponotus pennsylvanicus, trophallaxis—the exchange of regurgitated food—spreads compounds and prophylactic agents, enhancing nestmate resistance to pathogens like Metarhizium anisopliae. employ grooming and allogrooming to remove parasites from nestmates, as observed in species like Reticulitermes flavipes, where physical removal and antiseptic secretions collectively suppress fungal infections.01503-5) These behaviors function as an extended immune system at the colony level, compensating for the vulnerability arising from high-density living. Unlike vertebrates, immune responses exhibit no classical immunological , but evidence supports transgenerational immune priming, where prior exposure enhances resistance through epigenetic modifications. In insects like the Tribolium castaneum, parental infection induces and changes that upregulate genes in progeny, improving survival against the same . This priming is context-specific and heritable across generations, as demonstrated in bumblebees () exposed to bacterial challenges. Such mechanisms represent an evolutionary precursor to adaptive immunity in vertebrates.00128-6)

Pathogen evasion strategies

Pathogens have evolved sophisticated mechanisms to evade host immune responses, allowing them to persist, replicate, and cause disease. These strategies target both innate and adaptive immunity, often by exploiting or subverting normal cellular processes. By hiding from immune detection, modulating immune signaling, or rapidly altering surface antigens, microbes can avoid clearance and establish chronic infections. One prominent evasion tactic is intracellular hiding, where sequester themselves within host cells or structures to avoid extracellular immune surveillance. For instance, establishes latency by integrating its genome into the DNA of resting + T cells, rendering infected cells transcriptionally silent and invisible to cytotoxic T lymphocytes. This reservoir formation enables long-term persistence despite antiretroviral . Similarly, induces the formation of granulomas in the lungs, walled-off structures composed of immune cells that contain but do not eradicate the bacteria, allowing dormancy and reactivation under favorable conditions. Pathogens also directly modulate immune responses to dampen host defenses. Viruses like cause profound by infecting immune cells such as lymphocytes and dendritic cells, leading to reduced production and impaired T cell activation, which increases susceptibility to secondary infections. In bacteria, produces , a surface protein that binds the Fc region of IgG antibodies, preventing opsonization and while potentially redirecting antibodies away from the bacterial surface. Antigenic variation further enables evasion by altering pathogen surface molecules recognized by antibodies and T cells. Influenza viruses employ antigenic drift through gradual mutations in hemagglutinin and neuraminidase genes, and antigenic shift via reassortment of genome segments from different strains, both reducing the effectiveness of pre-existing immunity. The protozoan parasite Trypanosoma brucei, causative agent of African sleeping sickness, uses variant surface glycoprotein (VSG) switching, rapidly changing its coat protein expression from a repertoire of over 1,000 genes to evade antibody responses.30152-5) Recent insights from the pandemic highlight ongoing pathogen adaptations. The viral inhibits type I (IFN) signaling by binding to host receptors and blocking downstream pathways, thereby blunting innate antiviral responses and allowing unchecked replication in early infection stages. Paradoxically, can also induce a hyperinflammatory , characterized by excessive release of pro-inflammatory cytokines like IL-6 and TNF-α, which overwhelms the immune system and contributes to severe tissue damage.

Historical Development

Early discoveries

The practice of , an early form of against , originated in during the tenth century, where dried smallpox scabs were inhaled or inserted into the skin to induce a mild and confer . This technique spread to other regions, including the , and was introduced to England in 1718 by , who observed it during her time in and had her own children inoculated to demonstrate its efficacy. reduced smallpox mortality but carried risks, as it sometimes led to full-blown disease in recipients. In 1796, English physician Edward Jenner advanced immunization by developing the first vaccine, using cowpox—a milder related virus—to protect against smallpox. Jenner observed that milkmaids exposed to cowpox appeared immune to smallpox and tested this by inoculating an 8-year-old boy, James Phipps, with pus from a cowpox lesion on dairymaid Sarah Nelmes, followed by a later exposure to smallpox material, which failed to cause illness. He published his findings in 1798, coining the term "vaccine" from the Latin for cowpox (vacca), establishing a safer alternative to variolation that became widely adopted. During the 1880s, Russian-born zoologist identified phagocytosis as a key mechanism of immune defense while studying starfish larvae in , , where he observed mobile cells engulfing foreign particles. Extending his observations to vertebrates, Metchnikoff proposed that specialized , or , actively consume and destroy invading microbes, forming the basis of cellular immunity. His work, recognized with the 1908 Nobel Prize in Physiology or shared with , highlighted innate immune responses independent of antibodies. In 1890, German bacteriologist , collaborating with Shibasaburo Kitasato, discovered antitoxins in the blood serum of animals immunized against , demonstrating that these substances could neutralize the disease's and treat infected individuals. By injecting serum from recovered animals into patients, von Behring's serum therapy dramatically lowered mortality rates, marking the first successful use of . This breakthrough earned him the inaugural 1901 in Physiology or Medicine and paved the way for concepts. These empirical discoveries laid foundational observations that later informed key immunological theories.

Key immunological theories

Paul Ehrlich's side-chain theory, proposed in 1897, represented an early attempt to explain the specificity of immune responses at the cellular level. Ehrlich postulated that cells possess pre-formed receptor molecules, termed "side-chains," on their surfaces that function like locks fitting specific or keys. Upon binding, these side-chains are released into the bloodstream as antitoxins, neutralizing the invader, while the cell regenerates additional side-chains to replenish its receptors. This mechanism accounted for both the specificity of - interactions and the amplification of immune responses through increased receptor production. The theory laid foundational groundwork for understanding receptor-ligand interactions in and served as a precursor to later concepts of by emphasizing pre-existing cellular specificity rather than instructional models of antibody formation. Building on such ideas, Frank Macfarlane Burnet formalized the in his 1959 monograph, providing a comprehensive framework for adaptive immunity. The theory posits that the immune system comprises a diverse population of pre-committed clones, each bearing unique receptors specific to particular , generated randomly during development. encounter selects and activates the matching clone, triggering its proliferation and differentiation into effector cells, such as plasma cells producing , while also generating memory cells for enhanced secondary responses. This process explains the specificity, diversity, and memory of immune responses, with self-tolerance achieved through the elimination of autoreactive clones during . Burnet's model resolved debates over synthesis by rejecting template-based instruction in favor of germline-encoded variability, profoundly influencing modern . In parallel, Peter Medawar's work in the 1940s elucidated the concept of acquired immunological tolerance, demonstrating how the immune system could be rendered unresponsive to specific antigens under certain conditions. Through experiments with grafts in mice, Medawar and colleagues showed that injecting foreign cells into newborn animals induced a state of tolerance, allowing subsequent grafts from the same donor to be accepted without rejection. This phenomenon, observed in dizygotic twin naturally tolerant to each other's blood cells due to fetal exchanges, highlighted that tolerance arises from early antigenic exposure before immune maturity, preventing the development of reactive clones. Medawar's findings, which earned him the 1960 shared with Burnet, provided critical insights into self-nonself discrimination and paved the way for by revealing mechanisms to suppress allograft rejection. Charles Janeway's 1989 proposal revived interest in innate immunity by integrating it with adaptive responses through the theory. Janeway argued that the immune system distinguishes infectious nonself from noninfectious self via germline-encoded receptors on innate immune cells that detect conserved microbial patterns, rather than relying solely on the adaptive arm's antigen-specific recognition. These pattern recognition receptors, later identified as Toll-like receptors, provide initial signals to activate antigen-presenting cells, delivering costimulatory cues essential for adaptive immunity. This framework challenged the adaptive-centric view dominant since the mid-20th century, emphasizing innate immunity's evolutionary primacy and its role in priming T and B cell responses, thus reshaping immunological paradigms.

Modern advancements

The completion of the in 2003 marked a pivotal advancement in understanding the immune system by providing a complete reference sequence of the , enabling the systematic identification and annotation of genes involved in immunity. This effort cataloged approximately 20,000 protein-coding genes, among which around 1,500 are associated with immune functions, including the 10 (TLR) genes that play a central role in innate immune recognition of pathogens. following the project revealed extensive evolutionary diversity, with over 1,700 intact TLR sequences identified across vertebrate species, highlighting adaptations in immune sensing mechanisms. These discoveries facilitated targeted studies on immune gene regulation and variation, laying the groundwork for personalized . In the 2010s, single-cell RNA sequencing (scRNA-seq) emerged as a transformative technology for dissecting immune cell heterogeneity, allowing researchers to profile transcriptomes at the resolution of individual cells rather than bulk populations. This approach uncovered previously unrecognized subsets within immune cell types, such as diverse activation states in T cells and macrophages during or , revealing dynamic heterogeneity that bulk sequencing obscured. Seminal applications in demonstrated how scRNA-seq could map rare immune populations and their responses in health and disease, enhancing understanding of adaptive immune diversity and tissue-specific adaptations. The development of CRISPR-Cas9 gene editing in 2012 revolutionized immune system manipulation by enabling precise, efficient modifications to immune cells, including the creation of universal donor cells for therapies. By targeting genes like those encoding ( and II molecules, researchers engineered allogeneic T cells and stem cells that evade host immune rejection, reducing risks in transplantation and . This technology has been applied to enhance CAR-T cell therapies, where multiplex editing knocks out inhibitory receptors and inserts antigen-specific receptors, improving efficacy against tumors while minimizing off-target effects. Advancements in during the 2020s have integrated into immunogenicity prediction, exemplified by tools like NetMHCpan-4.1, which uses neural networks to forecast peptide-MHC binding affinities with high accuracy across diverse HLA alleles. These AI-driven models analyze epitope sequences to predict T-cell immunogenicity, accelerating vaccine and therapeutic design by identifying immunogenic candidates without extensive wet-lab validation. Such predictions have proven instrumental in neoantigen targeting for personalized cancer vaccines, achieving up to 90% accuracy in binding affinity forecasts for novel peptides. The advent of mRNA vaccines represented a in immune system modulation, particularly demonstrated by their rapid deployment against in , which elicited robust humoral and cellular responses through transient expression of antigens in host cells. Unlike traditional vaccines, mRNA platforms allow swift to emerging pathogens via modifications, bypassing lengthy processes and enabling tunable immune activation via delivery. This technology has expanded to therapeutic applications, such as in situ cancer vaccines that encode tumor antigens to prime antitumor immunity, underscoring its versatility in harnessing innate and adaptive responses. From 2023 to 2025, saw further progress in , with enhanced strategies for tumor immune escape and personalized treatments, as well as the 2025 in Physiology or Medicine awarded for discoveries in peripheral immune regulation mechanisms that complement central tolerance.

References

Add your contribution
Related Hubs
User Avatar
No comments yet.